绒毛膜癌转移基因的筛选及沉默相关基因对其侵袭力影响的研究
|
摘要
第一章高低侵袭力绒毛膜癌细胞株差异表达基因的筛选和鉴定
目的采用基因芯片技术比较高、低侵袭力绒毛膜癌细胞株JEG-3和JAR的基因表达谱,以筛选出与绒毛膜癌侵袭转移相关的基因,为阐明绒毛膜癌侵袭转移的分子机制提供理论依据。
方法(1)应用MTT和Matrigel体外侵袭试验检测不同人绒毛膜癌细胞系JEG-3与JAR之间增殖能力和侵袭能力的差异;(2)提取绒毛膜癌细胞株JEG-3和JAR的总RNA,反转录制备杂交探针,运用基因芯片进行杂交,杂交信号用Agilent Scanner扫描,用Imagene软件和Genespring软件分析和处理数据;(3)应用RT-PCR技术检测小窝蛋白-1(CAV-1)和血管内皮细胞生长因子B(VEGF-B)在JEG-3和JAR绒毛膜癌细胞株中的表达情况,进而验证基因芯片结果的可信度。
结果(1)JEG-3和JAR细胞之间增殖能力的差异无显著性(P＞0.05),但JEG-3细胞的侵袭能力显著高于JAR细胞(P＜0.05);(2)对绒毛膜癌JEG-3和JAR细胞株的基因表达谱分析,发现两者表达差异显著的基因有742个,其中在JEG-3细胞中321个基因表达上调,422个基因表达下调,上调基因中与细胞侵袭转移能力有关的基因有51个,其中差异最显著的前五位分别是纤维连接蛋白(FN)、基质金属蛋白酶-2(MMP-2)、尿激酶型纤溶酶原激活因子(uPA)、小窝蛋白-1(CAV-1)和血管内皮细胞生长因子B(VEGF-B);(3)CAV-1和VEGF-B mRNA在JEG-3细胞中的表达水平显著高于在JAR细胞中的表达水平,结果与基因芯片结果一致。
结论(1)多个侵袭转移相关基因的表达在绒毛膜癌JEG-3和JAR细胞间存在着差异;(2)基因芯片技术能有效地分析各细胞系的基因表达谱、为研究绒毛膜癌转移机制提供新的途径。
第二章靶向Caveolin-1 shRNA载体的构建和沉默效应观察
目的设计合成针对Caveolin-1基因的shRNA质粒载体,转染人绒毛膜癌高侵袭力细胞JEG-3,应用RNA干扰技术抑制JEG-3细胞中Caveolin-1基因,建立可用于研究Caveolin-1基因功能的JEG-3细胞模型。研究Caveolin-1 shRNA转染对人绒毛膜癌高侵袭力细胞株JEG-3中Caveolin-1表达及其对JEG-3细胞在体内、外浸润和转移能力的影响。旨在进一步明确Caveolin-1在人绒毛膜癌进展过程中的作用及机制,探讨将Caveolin-1作为靶分子,运用shRNA技术对人绒毛膜癌进行基因治疗的可行性。
方法(1)构建靶向抑制Caveolin-1基因表达的短发夹双链RNA(shRNA)真核表达载体pshRNA-Caveolin-1;(2)采用脂质体转染法将载体导入人绒毛膜癌高侵袭力细胞JEG-3中,利用G-418对转染细胞JEG-3进行稳定表达克隆筛选,获得稳定持续表达shRNA的JEG-3细胞;(3)用RT-PCR和Western Blot方法分别从mRNA和蛋白水平观察RNA干扰对Caveolin-1表达的抑制效应;(4)应用Matrigel体外侵袭试验检测Caveolin-1 shRNA对绒毛膜癌细胞的体外侵袭能力的影响;(5)建立裸鼠皮下异种移植模型,观察Caveolin-1 shRNA对绒毛膜癌细胞的体内侵袭、转移能力的影响。
结果(1)成功构建靶向抑制Caveolin-1基因的shRNA载体,并经测序证实;(2)建立可用于研究Caveolin-1基因功能的JEG-3细胞模型;(3)发现转染pshRNA-Caveolin-1的JEG-3细胞中Caveolin-1 mRNA及蛋白质的表达比空白组和阴性对照组JEG-3细胞中Caveolin-1 mRNA及蛋白质的表达均明显下降,差异具有显著性(P＜0.05);(4)通过Matrigel体外侵袭试验证明抑制Caveolin-1基因在JEG-3细胞中的表达可降低JEG-3细胞的体外侵袭能力(P＜0.05);(5)在对裸鼠模型研究中发现,抑制Caveolin-1基因在JEG-3细胞中的表达可使裸鼠皮下肿瘤的大小降低(P＜0.05),肿瘤细胞肺转移的发生率降低(P＜0.05)。
结论(1)细胞内表达shRNA可长期敲低靶基因的表达,可建立较理想的基因功能研究细胞模型。(2)Caveolin-1基因与人绒毛膜癌侵袭、转移相关,可能是一种新的肿瘤治疗靶分子。(3)RNA干扰有望为人绒毛膜癌基因治疗提供新策略。
第三章靶向VEGF-B shRNA载体的构建和沉默效应观察
目的:研究VEGF-B shRNA转染对人绒毛膜癌高侵袭力细胞株JEG-3中VEGF-B表达及JEG-3细胞体内外侵袭、转移、促进血管生成能力的影响。旨在进一步明确VEGF-B在人绒毛膜癌进展过程中所起的作用及机制,探讨将VEGF-B作为靶分子,运用shRNA技术对人绒毛膜癌基因治疗的可行性。
方法:(1)构建靶向抑制VEGF-B基因表达的短发夹双链RNA(shRNA)真核表达载体pshRNA-VEGF-B;(2)采用脂质体转染法将载体导入人绒毛膜癌高侵袭力细胞JEG-3中,利用G-418对转染细胞JEG-3进行稳定表达克隆筛选,获得稳定持续表达shRNA的JEG-3细胞;(3)用RT-PCR和Western Blot方法分别从mRNA和蛋白水平观察RNA干扰对VEGF-B表达的抑制效应;(4)应用Matrigel体外侵袭试验检测VEGF-B shRNA对绒毛膜癌细胞的体外侵袭能力的影响;(5)建立裸鼠皮下异种移植模型,观察VEGF-B shRNA对JEG-3细胞侵袭转移能力的影响;(6)采用免疫组织化学技术,检测移植瘤组织中VEGF-B的表达情况以及CD_(34)标记的MVD表达情况。
结果:(1)成功构建靶向抑制VEGF-B基因的shRNA载体,并经测序证实;(2)建立可用于研究VEGF-B基因功能的JEG-3细胞模型;(3)发现转染pshRNA-VEGF-B的JEG-3细胞中VEGF-B mRNA及蛋白质的表达比空白组和阴性对照组JEG-3细胞中VEGF-B mRNA及蛋白质的表达均明显下降,差异具有显著性(P＜0.05);(4)通过Matrigel体外侵袭试验证明抑制VEGF-B基因在JEG-3细胞中的表达可降低JEG-3细胞的体外侵袭能力(P＜0.05);(5)在对裸鼠模型研究中发现,抑制VEGF-B基因在JEG-3细胞中的表达可使裸鼠皮下肿瘤的大小降低(P＜0.05),肿瘤细胞肺转移的发生率亦有降低(P＜0.05);(6)VEGF-B在空白组和阴性对照组移植瘤中的表达较转染组高(P＜0.05),MVD在空白组和阴性对照组移植瘤中高表达,在转染组移植瘤中表达降低(P＜0.05);(7)相关性分析显示VEGF-B蛋白表达水平与绒毛膜癌血管生成能力之间成正相关。
结论:(1)细胞内表达shRNA可长期敲低靶基因的表达,可建立较理想的基因功能研究细胞模型。(2)VEGF-B在人绒毛膜癌中的表达与MVD呈正相关,提示微血管的形成与VEGF-B的调控有关,MVD增高是人绒毛膜癌发生侵袭和远处转移的基础。(3)由shRNA介导的RNAi技术可能是一种有效的肿瘤基因治疗新方法。
PartⅠIdentification of diferentially expressed genes in human choriocarcinoma cell lines with different metastasis potential
Objective In order to obtain choriocarcinoma metastasis-associated genes,the transcriptional profiles of human choriocarcinoma cell lines JEG-3(highly metastatic) and JAR(lowly metastatic) were compared using cDNA microarray
Methods(1) The different invasion and proliferation ability between JEG-3 and JAR cell lines was proved by Matrigel invasion assay and MTT assay in vitro;(2) Total RNA of human choriocarcinoma JEG-3 cells and JAR cells was extracted, purified to mRNA and then reversely transcripted to cDNA probe respectively.The cDNA probe of JEG-3 was labelled with Cy3 and the cDNA probe of JAR was labelled with Cy5.The two samples were hybridized with the cDNA microarray.The hybridization signals were scanned by Agilent Scanner and obtained data were analyzed using Imagene software and Genespring software.(3) In order to confirm the quality of gene chip,Reverse transcriptase polymerase chain reaction(RT-PCR) was carried out to determine CAV-1 and VEGFB gene expression.
Results(1) We proved that the invasion ability of JEG-3 cell line was stronger than that of JAR cell line(P＜0.05),but the difference of proliferation ability between JAR and JEG-3 is not obvious(P＞0.05);(2) 743 differential expression genes were found between JEG-3 and JAR cell lines by analyzing gene expression profile.There were 321 upregulated genes and 422 downregulated genes in JEG-3 cell line.In upregulated genes,there are 51 genes were correlated with the cell metastasis ability, and FN、MMP-2、uPA、CAV-1 and VEGF-B are the first five genes;(3) We found that the CAV-1 and VEGFB gene in JEG-3 were significantly higher than those in JAR cell lines(P＜0.05),the results of RT-PCR verified the gene chip further.
Conclusions(1) There were many differently expressed metastatic genes between JEG-3 and JAR cell lines;(2) The technology of cDNA microarray could analyze effectively gene expression profile of different cell lines,and supply a new approach to study the mechanism of choriocarcinoma metastasis
PartⅡConstruction of Caveolin-1 shRNA expressing vector and observation of its gene silencing effect
Objective Caveolin-1 gene specific shRNA expressing plasmid was constructed and then transfected into JEG-3 cells so cell model was established to study VEGF-B gene function.Investigate the effects of shRNA transfection on Caveolin-1 expression and the potential of invasion and metastasis in human choriocarcinoma cell lines JEG-3(highly metastatic) in vivo and vitro.To further identify the role and mechanism of Caveolin-1 in the progression of human choriocarcinoma and investigate the feasibility of using gene therapy of shRNA technology to treat human choriocarcinoma with Caveolin-1 as the target molecule.
Methods(1) Caveolin-1 gene specific shRNA expressing plasmid was constructed;(2) Caveolin-1 gene specific shRNA expressing plasmid is transfected into JEG-3 cells by lipofectamineTM 2000,non-transfected cells and non-specific shRNA were taken as controls;(3)Inhibitory effect of VEGF-B shRNA was demonstrated by RT-PCR and Western blot;(4) The effect of Caveolin-1 shRNA on invasion in JEG-3 cells in vitro was detected by Matrigel invasion assay;(5) The effects of Caveolin-1 shRNA on potential of invasion and metastasis in JEG-3 cells in vivo were observed using nude mice subcutaneous xenotransplantation model.
Results(1) Caveolin-1 gene specific shRNA expressing plasmid was constructed;(2) Caveolin-1 gene specific shRNA expressing plasmid is transfected into JEG-3 cells by lipofectamineTM 2000.Non-transfected cells and non-specific shRNA were taken as controls;(3)Inhibitory effect of Caveolin-1 shRNA was demonstrated by RT-PCR and Western blot,and there was a statistically significant difference comparing with the controls(P＜0.05);(4) Caveolin-1 shRNA transfection significantly downregulated invasion level of JEG-3 cells in vitro(P＜0.05);(5) Caveolin-1 shRNA transfection decreased the size of subcutaneous tumor(P＜0.05),and the pulmonary metastasis incidence is decreased also(P＜0.05).
Conclusions(1) Specific shRNA can mediate long-term and stable silencing effects on VEGF-B gene.(2) Caveolin-1 is correlated with cell proliferation,invasion and metastasis of human choriocarcinoma,and it might be a new tumor therapy target molecule.(3) RNAi is expected to supply new strategy for human choriocarcinoma.
PartⅢConstruction of VEGF-B shRNA expressing vector and observation of its gene silencing effect
Objective To investigate the effects of shRNA transfection on VEGF-B expression and the potential of invasion and metastasis and angiogenesis in human choriocarcinoma cell lines JEG-3(highly metastatic) in vivo.To further identify the role and mechanism of VEGF-B in the progression of human chorioearcinoma and investigate the feasibility of using gene therapy of shRNA technology to treat human choriocarcinoma with VEGF-B as the target molecule.
Methods(1)VEGF-B gene specific shRNA expressing plasmid was constructed;(2)VEGF-B gene specific shRNA expressing plasmid is transfected into JEG-3 cells by lipofectamineTM 2000.Non-transfected cells and non-specific shRNA were taken as eontrols;(3)Inhibitory effect of VEGF-B shRNA was demonstrated by RT-PCR and Western blot;(4) The effect of VEGF-B shRNA on invasion in JEG-3 cells in vitro was detected by Matrigel invasion assay;(5)The effects of VEGF-B shRNA on potential of invasion and metastasis in JEG-3 cells in vivo were observed using nude mice subcutaneous xenotransplantation model;(6) Immunohistochemical technology was performed to detect the VEGF-B and MVD(marked with CD34) in transplanted tumor.
Results(1)VEGF-B shRNA expressing plasmids were successfully constructed;(2)JEG-3 cell model was established to study VEGF-B gene function;(3)VEGF-B specific shRNA effectively inhibited the expression of VEGF-B at the mRNA and protein levels,and there was a statistically significant difference comparing with the controls(P＜0.05);(4) VEGF-B shRNA transfection significantly downregulated invasion level of JEG-3 cells in vitro(P＜0.05);(5) VEGF-B shRNA transfection decreased the size of subcutaneous tumor(P＜0.05),and the pulmonary metastasis incidence is decreased also(P＜0.05);(6)Strong VEGF-B expression was found in the control transplanted tumor,whereas weak expression in the transfected transplanted tumor,there was statistical difference between the control and the transfected(P＜0.05).High MVD expression was found in the control,whereas low expression in transfected,there was statistical difference between the groups(P＜0.05).There was positive relationship between VEGF-B and MVD expression;(7) The data suggested that there were significantly positive correlations between VEGF-B expression and the angiogenesis of choriocarcinoma.
Conclusions(1) Specific shRNA can mediate long-term and stable silencing effects on VEGF-B gene.(2) There is positive relationship between VEGF-B and MVD in human choriocarcinoma indicate the formation of microvessel is regulated by VEGF-B.Increasing MVD is the basis for invasion and metastases in human choriocarcinoma.(3) RNAi technology mediated by shRNA might be an effective tumor gene therapy method.
目的采用基因芯片技术比较高、低侵袭力绒毛膜癌细胞株JEG-3和JAR的基因表达谱,以筛选出与绒毛膜癌侵袭转移相关的基因,为阐明绒毛膜癌侵袭转移的分子机制提供理论依据。
方法(1)应用MTT和Matrigel体外侵袭试验检测不同人绒毛膜癌细胞系JEG-3与JAR之间增殖能力和侵袭能力的差异;(2)提取绒毛膜癌细胞株JEG-3和JAR的总RNA,反转录制备杂交探针,运用基因芯片进行杂交,杂交信号用Agilent Scanner扫描,用Imagene软件和Genespring软件分析和处理数据;(3)应用RT-PCR技术检测小窝蛋白-1(CAV-1)和血管内皮细胞生长因子B(VEGF-B)在JEG-3和JAR绒毛膜癌细胞株中的表达情况,进而验证基因芯片结果的可信度。
结果(1)JEG-3和JAR细胞之间增殖能力的差异无显著性(P＞0.05),但JEG-3细胞的侵袭能力显著高于JAR细胞(P＜0.05);(2)对绒毛膜癌JEG-3和JAR细胞株的基因表达谱分析,发现两者表达差异显著的基因有742个,其中在JEG-3细胞中321个基因表达上调,422个基因表达下调,上调基因中与细胞侵袭转移能力有关的基因有51个,其中差异最显著的前五位分别是纤维连接蛋白(FN)、基质金属蛋白酶-2(MMP-2)、尿激酶型纤溶酶原激活因子(uPA)、小窝蛋白-1(CAV-1)和血管内皮细胞生长因子B(VEGF-B);(3)CAV-1和VEGF-B mRNA在JEG-3细胞中的表达水平显著高于在JAR细胞中的表达水平,结果与基因芯片结果一致。
结论(1)多个侵袭转移相关基因的表达在绒毛膜癌JEG-3和JAR细胞间存在着差异;(2)基因芯片技术能有效地分析各细胞系的基因表达谱、为研究绒毛膜癌转移机制提供新的途径。
第二章靶向Caveolin-1 shRNA载体的构建和沉默效应观察
目的设计合成针对Caveolin-1基因的shRNA质粒载体,转染人绒毛膜癌高侵袭力细胞JEG-3,应用RNA干扰技术抑制JEG-3细胞中Caveolin-1基因,建立可用于研究Caveolin-1基因功能的JEG-3细胞模型。研究Caveolin-1 shRNA转染对人绒毛膜癌高侵袭力细胞株JEG-3中Caveolin-1表达及其对JEG-3细胞在体内、外浸润和转移能力的影响。旨在进一步明确Caveolin-1在人绒毛膜癌进展过程中的作用及机制,探讨将Caveolin-1作为靶分子,运用shRNA技术对人绒毛膜癌进行基因治疗的可行性。
方法(1)构建靶向抑制Caveolin-1基因表达的短发夹双链RNA(shRNA)真核表达载体pshRNA-Caveolin-1;(2)采用脂质体转染法将载体导入人绒毛膜癌高侵袭力细胞JEG-3中,利用G-418对转染细胞JEG-3进行稳定表达克隆筛选,获得稳定持续表达shRNA的JEG-3细胞;(3)用RT-PCR和Western Blot方法分别从mRNA和蛋白水平观察RNA干扰对Caveolin-1表达的抑制效应;(4)应用Matrigel体外侵袭试验检测Caveolin-1 shRNA对绒毛膜癌细胞的体外侵袭能力的影响;(5)建立裸鼠皮下异种移植模型,观察Caveolin-1 shRNA对绒毛膜癌细胞的体内侵袭、转移能力的影响。
结果(1)成功构建靶向抑制Caveolin-1基因的shRNA载体,并经测序证实;(2)建立可用于研究Caveolin-1基因功能的JEG-3细胞模型;(3)发现转染pshRNA-Caveolin-1的JEG-3细胞中Caveolin-1 mRNA及蛋白质的表达比空白组和阴性对照组JEG-3细胞中Caveolin-1 mRNA及蛋白质的表达均明显下降,差异具有显著性(P＜0.05);(4)通过Matrigel体外侵袭试验证明抑制Caveolin-1基因在JEG-3细胞中的表达可降低JEG-3细胞的体外侵袭能力(P＜0.05);(5)在对裸鼠模型研究中发现,抑制Caveolin-1基因在JEG-3细胞中的表达可使裸鼠皮下肿瘤的大小降低(P＜0.05),肿瘤细胞肺转移的发生率降低(P＜0.05)。
结论(1)细胞内表达shRNA可长期敲低靶基因的表达,可建立较理想的基因功能研究细胞模型。(2)Caveolin-1基因与人绒毛膜癌侵袭、转移相关,可能是一种新的肿瘤治疗靶分子。(3)RNA干扰有望为人绒毛膜癌基因治疗提供新策略。
第三章靶向VEGF-B shRNA载体的构建和沉默效应观察
目的:研究VEGF-B shRNA转染对人绒毛膜癌高侵袭力细胞株JEG-3中VEGF-B表达及JEG-3细胞体内外侵袭、转移、促进血管生成能力的影响。旨在进一步明确VEGF-B在人绒毛膜癌进展过程中所起的作用及机制,探讨将VEGF-B作为靶分子,运用shRNA技术对人绒毛膜癌基因治疗的可行性。
方法:(1)构建靶向抑制VEGF-B基因表达的短发夹双链RNA(shRNA)真核表达载体pshRNA-VEGF-B;(2)采用脂质体转染法将载体导入人绒毛膜癌高侵袭力细胞JEG-3中,利用G-418对转染细胞JEG-3进行稳定表达克隆筛选,获得稳定持续表达shRNA的JEG-3细胞;(3)用RT-PCR和Western Blot方法分别从mRNA和蛋白水平观察RNA干扰对VEGF-B表达的抑制效应;(4)应用Matrigel体外侵袭试验检测VEGF-B shRNA对绒毛膜癌细胞的体外侵袭能力的影响;(5)建立裸鼠皮下异种移植模型,观察VEGF-B shRNA对JEG-3细胞侵袭转移能力的影响;(6)采用免疫组织化学技术,检测移植瘤组织中VEGF-B的表达情况以及CD_(34)标记的MVD表达情况。
结果:(1)成功构建靶向抑制VEGF-B基因的shRNA载体,并经测序证实;(2)建立可用于研究VEGF-B基因功能的JEG-3细胞模型;(3)发现转染pshRNA-VEGF-B的JEG-3细胞中VEGF-B mRNA及蛋白质的表达比空白组和阴性对照组JEG-3细胞中VEGF-B mRNA及蛋白质的表达均明显下降,差异具有显著性(P＜0.05);(4)通过Matrigel体外侵袭试验证明抑制VEGF-B基因在JEG-3细胞中的表达可降低JEG-3细胞的体外侵袭能力(P＜0.05);(5)在对裸鼠模型研究中发现,抑制VEGF-B基因在JEG-3细胞中的表达可使裸鼠皮下肿瘤的大小降低(P＜0.05),肿瘤细胞肺转移的发生率亦有降低(P＜0.05);(6)VEGF-B在空白组和阴性对照组移植瘤中的表达较转染组高(P＜0.05),MVD在空白组和阴性对照组移植瘤中高表达,在转染组移植瘤中表达降低(P＜0.05);(7)相关性分析显示VEGF-B蛋白表达水平与绒毛膜癌血管生成能力之间成正相关。
结论:(1)细胞内表达shRNA可长期敲低靶基因的表达,可建立较理想的基因功能研究细胞模型。(2)VEGF-B在人绒毛膜癌中的表达与MVD呈正相关,提示微血管的形成与VEGF-B的调控有关,MVD增高是人绒毛膜癌发生侵袭和远处转移的基础。(3)由shRNA介导的RNAi技术可能是一种有效的肿瘤基因治疗新方法。
PartⅠIdentification of diferentially expressed genes in human choriocarcinoma cell lines with different metastasis potential
Objective In order to obtain choriocarcinoma metastasis-associated genes,the transcriptional profiles of human choriocarcinoma cell lines JEG-3(highly metastatic) and JAR(lowly metastatic) were compared using cDNA microarray
Methods(1) The different invasion and proliferation ability between JEG-3 and JAR cell lines was proved by Matrigel invasion assay and MTT assay in vitro;(2) Total RNA of human choriocarcinoma JEG-3 cells and JAR cells was extracted, purified to mRNA and then reversely transcripted to cDNA probe respectively.The cDNA probe of JEG-3 was labelled with Cy3 and the cDNA probe of JAR was labelled with Cy5.The two samples were hybridized with the cDNA microarray.The hybridization signals were scanned by Agilent Scanner and obtained data were analyzed using Imagene software and Genespring software.(3) In order to confirm the quality of gene chip,Reverse transcriptase polymerase chain reaction(RT-PCR) was carried out to determine CAV-1 and VEGFB gene expression.
Results(1) We proved that the invasion ability of JEG-3 cell line was stronger than that of JAR cell line(P＜0.05),but the difference of proliferation ability between JAR and JEG-3 is not obvious(P＞0.05);(2) 743 differential expression genes were found between JEG-3 and JAR cell lines by analyzing gene expression profile.There were 321 upregulated genes and 422 downregulated genes in JEG-3 cell line.In upregulated genes,there are 51 genes were correlated with the cell metastasis ability, and FN、MMP-2、uPA、CAV-1 and VEGF-B are the first five genes;(3) We found that the CAV-1 and VEGFB gene in JEG-3 were significantly higher than those in JAR cell lines(P＜0.05),the results of RT-PCR verified the gene chip further.
Conclusions(1) There were many differently expressed metastatic genes between JEG-3 and JAR cell lines;(2) The technology of cDNA microarray could analyze effectively gene expression profile of different cell lines,and supply a new approach to study the mechanism of choriocarcinoma metastasis
PartⅡConstruction of Caveolin-1 shRNA expressing vector and observation of its gene silencing effect
Objective Caveolin-1 gene specific shRNA expressing plasmid was constructed and then transfected into JEG-3 cells so cell model was established to study VEGF-B gene function.Investigate the effects of shRNA transfection on Caveolin-1 expression and the potential of invasion and metastasis in human choriocarcinoma cell lines JEG-3(highly metastatic) in vivo and vitro.To further identify the role and mechanism of Caveolin-1 in the progression of human choriocarcinoma and investigate the feasibility of using gene therapy of shRNA technology to treat human choriocarcinoma with Caveolin-1 as the target molecule.
Methods(1) Caveolin-1 gene specific shRNA expressing plasmid was constructed;(2) Caveolin-1 gene specific shRNA expressing plasmid is transfected into JEG-3 cells by lipofectamineTM 2000,non-transfected cells and non-specific shRNA were taken as controls;(3)Inhibitory effect of VEGF-B shRNA was demonstrated by RT-PCR and Western blot;(4) The effect of Caveolin-1 shRNA on invasion in JEG-3 cells in vitro was detected by Matrigel invasion assay;(5) The effects of Caveolin-1 shRNA on potential of invasion and metastasis in JEG-3 cells in vivo were observed using nude mice subcutaneous xenotransplantation model.
Results(1) Caveolin-1 gene specific shRNA expressing plasmid was constructed;(2) Caveolin-1 gene specific shRNA expressing plasmid is transfected into JEG-3 cells by lipofectamineTM 2000.Non-transfected cells and non-specific shRNA were taken as controls;(3)Inhibitory effect of Caveolin-1 shRNA was demonstrated by RT-PCR and Western blot,and there was a statistically significant difference comparing with the controls(P＜0.05);(4) Caveolin-1 shRNA transfection significantly downregulated invasion level of JEG-3 cells in vitro(P＜0.05);(5) Caveolin-1 shRNA transfection decreased the size of subcutaneous tumor(P＜0.05),and the pulmonary metastasis incidence is decreased also(P＜0.05).
Conclusions(1) Specific shRNA can mediate long-term and stable silencing effects on VEGF-B gene.(2) Caveolin-1 is correlated with cell proliferation,invasion and metastasis of human choriocarcinoma,and it might be a new tumor therapy target molecule.(3) RNAi is expected to supply new strategy for human choriocarcinoma.
PartⅢConstruction of VEGF-B shRNA expressing vector and observation of its gene silencing effect
Objective To investigate the effects of shRNA transfection on VEGF-B expression and the potential of invasion and metastasis and angiogenesis in human choriocarcinoma cell lines JEG-3(highly metastatic) in vivo.To further identify the role and mechanism of VEGF-B in the progression of human chorioearcinoma and investigate the feasibility of using gene therapy of shRNA technology to treat human choriocarcinoma with VEGF-B as the target molecule.
Methods(1)VEGF-B gene specific shRNA expressing plasmid was constructed;(2)VEGF-B gene specific shRNA expressing plasmid is transfected into JEG-3 cells by lipofectamineTM 2000.Non-transfected cells and non-specific shRNA were taken as eontrols;(3)Inhibitory effect of VEGF-B shRNA was demonstrated by RT-PCR and Western blot;(4) The effect of VEGF-B shRNA on invasion in JEG-3 cells in vitro was detected by Matrigel invasion assay;(5)The effects of VEGF-B shRNA on potential of invasion and metastasis in JEG-3 cells in vivo were observed using nude mice subcutaneous xenotransplantation model;(6) Immunohistochemical technology was performed to detect the VEGF-B and MVD(marked with CD34) in transplanted tumor.
Results(1)VEGF-B shRNA expressing plasmids were successfully constructed;(2)JEG-3 cell model was established to study VEGF-B gene function;(3)VEGF-B specific shRNA effectively inhibited the expression of VEGF-B at the mRNA and protein levels,and there was a statistically significant difference comparing with the controls(P＜0.05);(4) VEGF-B shRNA transfection significantly downregulated invasion level of JEG-3 cells in vitro(P＜0.05);(5) VEGF-B shRNA transfection decreased the size of subcutaneous tumor(P＜0.05),and the pulmonary metastasis incidence is decreased also(P＜0.05);(6)Strong VEGF-B expression was found in the control transplanted tumor,whereas weak expression in the transfected transplanted tumor,there was statistical difference between the control and the transfected(P＜0.05).High MVD expression was found in the control,whereas low expression in transfected,there was statistical difference between the groups(P＜0.05).There was positive relationship between VEGF-B and MVD expression;(7) The data suggested that there were significantly positive correlations between VEGF-B expression and the angiogenesis of choriocarcinoma.
Conclusions(1) Specific shRNA can mediate long-term and stable silencing effects on VEGF-B gene.(2) There is positive relationship between VEGF-B and MVD in human choriocarcinoma indicate the formation of microvessel is regulated by VEGF-B.Increasing MVD is the basis for invasion and metastases in human choriocarcinoma.(3) RNAi technology mediated by shRNA might be an effective tumor gene therapy method.
引文
[1]Higashijima S,Nose A,Eguchi G,et al.Mindin/F spondin family:novel ECM proteins expressed in the zebrafish embryonic axis.Dev Biol,1997,192(2):211-227
[2]Mutsaers SE,Bishop JE,McGrouther G,et al.Mechanisms of tissue repair:from wound healing to fibrosis.Int J Biochem Cell Biol,1997,29(1):5-17.
[3]Grummer R,Hohn HP,Mareel MM,et al.Adhesion and invasion of three human choriocarcinoma cell lines into human endometrium in a three dimensional organ culture system J.Placenta,1994,15:411-429.
[4]Frank PG,Lisanti MP.Caveolin-1 and liver regeneration:role in proliferation and lipogenesis.Cell Cycle,2007,6(2):115-116.
[5]Tsutsui S,Kume M,Era S.Prognostic value of microvessel density in invasive ductal carcinoma of the breast.Breast Cancer,2003,10(4):312-319.
[6]Olofsson B,Pajusola K,Kaipainen A,et al.Vascular endothelial growth factor B,a novel growth factor for endothelial cells.Pro Natl Acad Sci USA,1996,93(6):2576-2581.
[7]Grimmond S,Lagercrantz J,Drinkwater C,et al.Cloning and characterization of a novel human gene related to vascular endothelial growth factor.Genome Res,1996,6:124-131.
[8]Krichevsky AM,Kosik KS.RNAi funcrions in cultured mammalian nurons.Proc Natl Acad Sci USA,2002,99(18):11926-11929.
[9]Wilda M,Fuchs U,Wossmann W,et al.Killing of leukemic cells with a BCR-ABL fusion gene by RNA interference(RNAi).Oncogene,2002,21(37):5716-5724.
[10]Lin SL,Chuong CM,Ying SY.A novel mRNA-cDNA interference phenomenon for silencing bcl-2 expression in human LNCaP cells.Biochem Biophys Res Commun,2001,281(3):639-643.
[1]Higashijima S,Nose A,Eguchi G,et al.Mindin/F spondin family:novel ECM proteins expressed in the zebrafish embryonic axis.Dev Biol,1997,192(2):211-227
[2]Mutsaers SE,Bishop JE,McGrouther G,et al.Mechanisms of tissue repair:from wound healing to fibrosis.Int J Biochem Cell Biol,1997,29(1):5-17.
[3]Grummer R,Hohn HP,Mareel MM,et al.Adhesion and invasion of three human choriocarcinoma cell lines into human endometrium in a three dimensional organ culture system J.Placenta,1994,15:411-429
[4]Yang YJ,Zhang YL,Li X,et al.Contribution of eIF-4E inhibition to the expression and activity of heparanase in human colon adenocarcinoma cell line:LS- 174T.World J Gastroenterol,2003,9(8):1707-1712
[5]Maxhimer JB,Quiros RM,Stewart R,et al.Heparanase-1 expression is associated with the metastatic potential of breast cancer.Surgery,2002,132(2):326-333
[6] Vlodavsky I, Elkin M, Pappo O, et al. Mammalian heparanase as mediator of tumor metastasis and angiogenesis. Isr Med Assoc J,2000,2,suppl:37-45
[7] Zeeberg BR, Feng W, Wang G, et al. GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol,2003,4(4): R28
[8] Borgfeldt C, Casslen B, Liu CL, et al. High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma. Int J Cancer, 1998,79(6):588-595
[9] O'Toole S, McGuinness E, Sheppard B, et al. Plasminogen activators and inhibitors in ovarian adenocarcinomas. Int J Gynecol Cancer,1999,9(l): 61-66
[10] Borgfeldt C, Hansson SR, Gustavsson B, et al. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). Int J Cancer,2001,15, 92(4): 497-502
[11] Abendstein B, Daxenbichler G, Windbichler G, et al. Predictive value of uPA,PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients. Anticancer Res, 2000, 20(1B):569-572
[12] Hapke S, Kessler H, Arroyo de Prada N, et al. Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J Biol Chem,2001,13, 276 (28):26340-26348
[13] Delia Porta P, Soeltl R, Krell HW, et al. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo. Anticancer Res,1999,19(5B):3809-3816
[14] Marshall A, Hodgson J. DNA chips: an array of possibilities. Nat Biotechnol,1998, 16(1):27-31
[15] Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature, 1980, 283 (5743): 139-146
[16] Schena M, Shalon D, Davis RW, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science, 1995, 270(5235):467-470
[17] DeRisi J, Penland L, Brown PO, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet,1996,14(4):457-460
[18]Jingting C,Yangde Z,Yi Z,et al.Heparanase expression correlates with metastatic capability in human choriocarcinoma.Gynecol Oncol,2007,107(1):22-29
[19]Yu R,Zhang Y,Cai JT.Correlation between expression of heparanase and invasion of choriocarcinoma.Zhonghua Fu Chan Ke Za Zhi,2007,42(10):692-695
[20]Diaz LE,Chuan YC,Lewitt M,et al.IGF-Ⅱ regulates metastatic properties of choriocarcinoma cells through the activation of the insulin receptor.Mol Hum Reprod,2007,13(8):567-576
[21]Pongcharoen S,Niumsup P,Sanguansermsri D,et al.The effect of interleukin-17 on the proliferation and invasion of JEG-3 human choriocarcinoma cells.Am J Reprod Immunol,2006,55(4):291-300
[22]Hume DA.The mononuclear phagocyte system.Curr Opin Immunol,2006,18(1):49-53
[23]Patel VP,Lodish HF.A fibronectin matrix is required for differentiation of murine erythroleukemia cells into reticulocytes.J Cell Biol,1987,105(6 Pt 2):3105-3118
[24]Damiano JS,Cress AE,Hazlehurst LA,et al.Cell adhesion mediated drug resistance(CAM-DR):role of integrins and resistance to apoptosis in human myeloma cell lines.Blood,1999,93(5):1658-1667
[25]Sethi T,Rintoul RC,Moore SM,et al.Extracellular matrix proteins protect small cell lung cancer cells against apoptosis:a mechanism for small cell lung cancer growth and drug resistance in vivo.Nat Med,1999,5(6):662-668
[26]Qwarnstr(o|¨)m EE,Ostberg CO,Turk GL,et al.Fibronectin attachment activates the NF-kappa B p50/p65 heterodimer in fibroblasts and smooth muscle cells.J Biol Chem,1994,269(49):30765-30768
[27]Mohri H,Katoh K,Iwamatsu A,et al.The novel recognition site in the C-terminal heparin-binding domain of fibronectin by integrin alpha 4 beta 1receptor on HL-60 cells.Exp Cell Res,1996,222(2):326-332.
[28]Coll JM,Luborsky SW,Mora PT.Metabolically labeled cell membrane proteins in spontaneously and in SV40 virus transformed mouse fibroblasts.Biochemistry,1977,16(14):3169-3177
[29]Liotta LA,Stetler-Stevenson WG.Tumor invasion and metastasis:an imbalance of positive and negative regulation.Cancer Res,1991,51(18 Suppl):5054-5059
[30]Chambers AF,Matrisian LM.Changing views of the role of matrix metalloproteinases in metastasis.J Natl Cancer Inst,1997,89(17):1260- 1270
[31]Parsons SL,Watson SA,Collins HM,et al.Gelatinase(MMP-2 and -9)expression in gastrointestinal malignancy.Br J Cancer,1998,78(11):1495-1502
[32]Nomura H,Fujimoto N,Seiki M,et al.Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2(gelatinase A) in human gastric carcinomas.Int J Cancer,1996,69(1):9-16
[33]Poulsom R,Pignatelli M,Stetler-Stevenson WG,et al.Stromal expression of 72kda type Ⅳ collagenase(MMP-2) and TIMP-2 mRNAs in colorectal neoplasia.Am J Pathol,1992,141(2):389-396
[34]Gohji K,Fujimoto N,Hara I,et al.Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension.Int J Cancer,1998,79(1):96-101
[35]Lampert K,Machein U,Machein MR,et al.Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors.Am J Pathol,1998,153(2):429-37.
[36]陈洪雷,刁路明,陈德基,等.大鼠肺癌侵袭和转移中明胶酶A及其抑制剂的动态表达.中华肿瘤杂志,2002,24(2):118-122.
[37]陈龙邦,李桂圆,王靖华,等.MMP-2和TIMP-2在非小细胞肺癌中的表达及其临床意义.肿瘤防治杂志,2003,10(6):8
[38]Staun-Ram E,Goldman S,Gabarin D,et al.Expression and importance of matrix metalloproteinase 2 and 9(MMP-2 and -9) in human trophoblast invasion.Reprod Biol Endocrinol,2004,2:59
[39]Okamoto T,Niu R,Yamada S,et al.Reduced expression of tissue inhibitor of metalloproteinase(TIMP)-2 in gestational trophoblastic diseases.Mol Hum Reprod,2002,8(4):392-398
[40]Ganesh S,Sier CF,Heerding MM,et al.Prognostic value of the plasminogen activation system in patients with gastric carcinoma.Cancer,1996,77(6):1035-1043
[41]Hong SI,Park IC,Son YS,et al.Expression of urokinase-type plasminogen activator,its receptor,and its inhibitor in gastric adenocarcinoma tissues.J Korean Med Sci,1996,11(1):33-37
[42]He Y,Liu XD,Chen ZY,et al.Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.Clin Cancer Res,2007,13(11):3115-3124
[43]Nekarda H,Schlegel P,Schmitt M,et al.Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.Clin Cancer Res,1998,4(7):1755-1763
[44]周立,芮静安,王少斌,等.尿激酶型纤溶酶原激活剂(uPA)和其受体(uPAR)在肝细胞癌的表达及其临床和病理.中国微创外科杂志,2002,2(6):422-423
[45]van der Burg ME,Henzen-Logmans SC,Berns EM,et al.Expression of urokinase-type plasminogen activator(uPA) and its inhibitor PAI-1 in benign,borderline,malignant primary and metastatic ovarian tumors.Int J Cancer,1996,69(6):475-479
[46]Chambers SK,Ivins CM,Carcangiu ML.Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients.Int J Cancer,1998,79(5):449-454
[47]Gleeson NC,Gonsalves R,Bonnar J.Plasminogen activator inhibitors in endometrial adenocarcinoma.Cancer,1993,72(5):1670-1672
[48]Glenney J R Jr,Zokas L.Nove ltyrosine kinase substrates from Rous Sarcoma Virus-transformed cell are present in the membrane skekton.J Cell Biol,1989,108(6):2401-2408.
[49]Frank PG,Lisanti MP.Caveolin-1 and liver regeneration:role in proliferation and lipogenesis.Cell Cycle,2007,6(2):115-116
[50]Torres VA,Tapia JC,Rodriguez DA,et al.Caveolin-1 controls cell proliferation and cell death by suppressing expression of the inhibitor of apoptosis protein survivin.J Cell Sci,2006,119(Pt9):1812-1823
[51]Iguchi K,Matsunaga S,Nakano T,et al.Inhibition of caveolin-1 expression by incadronate in PC-3 prostate cells.Anticancer Res,2006,26(4B):2977-2981
[52]Kato K,Hida Y,Miyamoto M,et al.Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage.Cancer,2002,94(4):929-933
[53]Kim HA,Kim KH,Lee RA.Expression of caveolin-1 is correlated with Akt-1 in colorectal cancer tissues.Exp Mol Pathol,2006,80(2):165-170
[54]Hayashi K,Matsuda S,Machida K,et al.Invasion activating caveolin-1mutation in human scrirhous breast cancers.Cancer Res,2001,61(6):2361-2364
[55]Brkovic a,Sirois MG.Vascular permeability induced by VEGF family members in vivo:role of endogenous PAF and NO synthesis.J Cell Biochem, 2007,100(3):727-737.
[56]Grimmond S,Lagercrantz J,Drinkwater C,et al.Cloning and characterization of a novel human gene related to vascular endothelial growth factor.Genome Res,1996,6(2):124-131.
[57]Salver P,Lymboussaki A,Heikkila P,et al.Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors.Am J Pathol,1998,153:103-108.
[58]Iyer S,Scotney PD,Nash AD,et al.Crystal structure of human vascular endothelial growth factor-B:identification of amino acids important for receptor binding.J Mol Biol,2006,359(1):76-85.
[59]Olofsson B,Korpelainen E,Pepper MS,et al.Vascular endothelial growth B(VEGF-B) binds to VEGF receptors-1 and cells.Proc Natl Acad Sci USA,1998,95(20):11709-11714.
[60]Gunningham SP,Currie MJ,Ham C,et al.VEGF-B expression in human primary greast cancer is associated with lymph node metastasis but not angiogenesis.J Pathol,2001,193(3):325-332.
[61]Mylona E,Alexandrou P,Giannopoulou I,et al.The prognostic value of vascular endothelial growth factors(VEGFs)-A and -B and their receptor,VEGFR-1,in invasive breast carcinoma.Gynecol Oncol,2007,104(3):557-563.
[62]Mylona E,Alexandrou P,Giannopoulou I,et al.The prognostic value of vascular endothelial growth factors(VEGFs)-A and-B and their receptor,VEGFR-1,in invasive breast carcinoma.Gynecol Oncol,2007,104(3):557-563.
[63]Fitzpatrick TE,Lash GE,Yanaihara A,et al.Inhibition of breast carcinoma and trophoblast cell invasiveness by vascular endothelial growth factor.Exp Cell Res,2003,283(2):247-255.
[64]de Jong JS,van Diest PJ,van der Valk P,et al.Expression of growth factors,growth receptors and apoptosis related proteins in invasive breast cancer:relation to apoptotic rate.Breast Cancer Res Treat,2001,66(3):201-208.
[1]Rajjayabun PH,Garg S,Durkan GC,et al.Caveolin-1 expression is associated with high-grade bladder cancer.Urology,2001,58(5):811-814.
[2]Fra AM,Pasqualetto E,Mancini M,et al.Genomic organization and transcriptional analysis of the human genes coding for caveolin-1 and caveolin-2.Gene,2000,243:75-83.
[3]Hatanaka M,Maeda T,Ikemoto T,et al.Expression of caveolin-1 in human T cell leukemia cell lines.Biochem Biophys Res Comm,1998,253:382-387.
[4]Harris J,Werling D,Hope JC,et al.Caveolae and caveolin in immune cells:distribution and functions.Trends Immuno,2002,23(3):158- 164.
[5]Fujimoto T.Cell biology of caveolae and its implication for clinical medicine.Nagoya J Med Sci,2000,63:9-18.
[6]Bender FC,Reymond MA,Bron C,et al.Caveolin-1 levels are down- regulated in human colon tumors,and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity.Cancer Res,2000,60(20):5870-5878.
[7]Yang G,Truong LD,Timmme TL,et al.Elevated expression of caveolin is associated with prostate and breast cancer.Clin Cancer Res,1998,4(8):1873-1880.
[8]Krichevsky AM,Kosik KS.RNAi funcrions in cultured mammalian nurons.Proc Natl Acad Sci USA,2002,99(18):11926-11929.
[9]Hammond SM,Bernstein E,Beach D,et al.An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells.Nature,2000,404(6775):293-296.
[10]Bernstein E,Caudy AA,Hammond SA,et al.Role for a bidentate ribonuclease in the initiation step of RNA interference.Nature,2001,409(6818):363-366.
[11]Sharp PA.RNA Interference-2001.Cenes Dev,2001,15(5):485-490.
[12]Shi Y.Mammalian RNAi for the masses.Trends Genet,2003,19(1):9- 12.
[13]Brummelkamp TR,Bernards B,Agami R.A system for expression of short interfering RNAs in mammalian cells.Science,2002,296:550-553.
[14]Poste G,Fidler IJ.The pathogenesis of cancer metastasis.Nature,1980,283(5743):139-146.
[15]Glenney JR,Zokas L.Nove Ityrosine kinase substrates from Rous Sarcoma Virus-transformed cell are present in the membrane skekton.J Cell Biol,1989,108(6):2401-2408.
[16]Frank PG,Lisanti MP.Caveolin-1 and liver regeneration:role in proliferation and lipogenesis.Cell Cycle,2007,6(2):115-116.
[17]Torres VA,Tapia JC,Rodriguez DA,et al.Caveolin-1 controls cell proliferation and cell death by suppressing expression of the inhibitor of apoptosis protein survivin.J Cell Sci,2006,119(Pt 9):1812-1823.
[18]Iguchi K,Matsunaga S,Nakano T,et al.Inhibition of caveolin-1 expression by incadronate in PC-3 prostate cells.Anticancer Res,2006,26(4B):2977-2981.
[19]Kato K,Hida Y,Miyamoto M,et al.Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage.Cancer,2002,94(4):929-933.
[20]Kim HA,Kim KH,Lee RA.Expression ofcaveolin-1 is correlated with Akt-1 in colorectal cancer tissues.Exp Mol Pathol,2006,80(2):165-170.
[21]Hayashi K,Matsuda S,Machida K,et al.Invasion activating caveolin-1mutation in human scrirhous breast cancers.Cancer Res,2001,61(6):2361-2364.
[22]Fire A,Xu S,Montgometry MK,et al.Potent and specific genetic interference by double-stranded RNA in Caenarhabditis elegans.Nature,1998,391(6669):806-811.
[23]Philip AB,Sunil SK,David MB.Tissue repair and stem cell renewal in carcinogenesis.Nature,2004,432:324-331.
[24]Yu JY,Deruiter SL,Turner DL.RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells.Proc Natl Acad Sci,2002,99(9):6047-6053.
[25]Couet J,Sargiacomo M,Lisanti MP.Interaction of a receptor tyrosine kinase,EGF-R,with eaveolins Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities.J Biol Chem,2004,272:30428-30438.
[26]Corely-Mastick C,Saltiel AR.Insulin-stimulated tyrosin phosphorylation of caveolin is specific for the differentiated adipocyte phenotype in 3T3-L1 cells.Biol Chem,2005,272:20706-20714.
[27]Wilda M,Fuchs U,Wossmann W,et al.Killing of leukemic cells with a BCR-ABL fusion gene by RNA interference(RNAi).Oncogene,2002,21(37):5716-5724.
[28]Scherr M,Battmer K,Winkler T,et al.Specific inhibition of bcrabl gene expression by small interfering RNA.Blood,2003,101(4):1566-1569.
[29]Wohlbold L,Van Der Kuip H,Miething C,et al.Inhibition of bcr- abl gene expression by small interfering RNA sensitizes for imatinib mesylate(STI571).Blood,2003,102(6):2236-2239.
[30]Brummelkamp TR,Bernards R,Agami R.Stable suppression of tumorigenicity by virus-mediated RNA interference.Cancer Cell,2002,2(3):243-247.
[31]Lin SL,Chuong CM,Ying SY.A novel mRNA-cDNA interference phenomenon for silencing bcl-2 expression in human LNCaP cells.Biochem Biophys Res Commun,2001,281(3):639-643.
[32]Elbashir SM,Harborth J,Lendeckel W,et al.Duplexes of 21- nuckeotide RNAs mediate RNA interference in cultured mammalian cells.Nature,2001,411(6836):494-498.
[33]Kleinman H,MacGarvey M,Hassell J,et al.Basement membrane complexes with biological activity.Biochemistry,1986,25(2):312-318.
[34]Albini A,Iwamoto Y,Kleinman HK,et al.A rapid in vitro assay for quantitating the invasive potential of tumor cells.Cancer Res,1987,47(12):3239-3245.
[35]Rozic JG,Chakraborty C,Lala PK.Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration,incasicenss and angiogenesis.Int J Cancer,2001,93(4):497-506.
[36]Hanna N,Fidler J.Expression of metastatic potential of allogeneic and enogeneic neoplasms in young nude mice.Cancer Res,1981,41(2):438-444.
[1]Anderson WF.Human Gene Therapy.Nature,1998,392(suppl):25-30.
[2]http://www.wiley.co.uk/genmed/clinical
[3]Brkovic a,Sirois MG.Vascular permeability induced by VEGF family members in vivo:role of endogenous PAF and NO synthesis.J Cell Biochem,2007,100(3):727-737.
[4]Wu Y,Zhong Z,Huber J,et al.Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.Clin Cancer Res,2006,12(21):6573-6584.
[5]Gisterek I,Komafel J.VEGF and its receptors as therapeutic target in cancer therapy.Przegl Lek,2006,63(3):155-157.
[6]Weidner N,Semple JP,Welch WR,et al.Tumor angiogenesis and metastasis:correlation in invasive breast carcinoma.N EngI J Med,1999,324:1-8.
[7]Salver P,Lymboussaki A,Heikkila P,et al.Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors.Am J Pathol,1998,153:103-108.
[8]Folkman J.Clinical applications of research on angiogenesis.N EngI J Med,2004,303(26):1757-1763.
[9]Roskoski R Jr.Vascular endothelial growth factor(VEGF) signaling in tumor progression.Crit Rev Oncol Hematol,2007,62(3):179- 213.
[10]Iyer S,Scotney PD,Nash AD,et al.Crystal structure of human vascular endothelial growth factor-B:identification of amino acids important for receptor binding.J Mol Biol,2006,26,359(1):76-85.
[11]Olofsson B,Pajusola K,Kaipainen A,et al.Vascular endothelial growth factor B,a novel growth factor for endothelial cells.Pro Natl Acad Sci USA,1996,93(6):2576-2581.
[12]Miyake S,Makimura M,Kanegae Y,et al.Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci USA,1996,93:1320-1324.
[13] Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA, 1998,95(20): 11709-11714.
[14] Gunningham SP, Currie MJ, Ham C, et al. VEGF-B expression in human primary greast cancer is associated with lymph node metastasis but not angiogenesis.J Pathol,2001,193(3):325-332.
[15] Eleni Mylona, Paraskevi Alexandrou, Loanna Giannopoulou, et al. The prognostic value of vascular endothelial growth factors(VEGFs)-A and -B and their receptor, VEGFR-1,in invasive breast carcinoma. Gynecol Oncol,2007,104(3):557-563.
[16] Fitzpatrick TE, Lash GE, Yanaihara A, et al. Inhibition of breast carcinoma and trophoblast cell invasiveness by vascular endothelial growth factor.Exp Cell Res,2003,283(2):247-255.
[17] deJong JS, vanDiest PJ, vanderValk P, et al. Expression of growth factors,growth receptors and apoptosis related proteins in invasive breast cancer:relation to apoptotic rate. Breast Cancer Res,2001,66:201- 208.
[18] Wey JS, Fan F, Gray MJ, et al. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer,2005,104(2):427-438.
[19] Ai JH, Zheng SG, Zeng YY, et al. The expression and significance of vascular endothelial growth factor and its receptors in hepatocellular carcinoma cell lines with various metastatic potentialities. Zhonghua Gan Zang Bing Za Zhi,2008,16(2):105-108.
[20] Yang AD, Camp ER, Fan F, et al. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res,2006,66(l):46-51.
[21] Wey JS, Fan F, Gray MJ, et al. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines.Cancer,2005,104(2):427-438.
[22] Canoglu A, Gogus C, Beduk Y, et al. Microvessel density as a prognostic marker in bladder carcinoma: correlation with humor grade, stage and prognosis.Int Urol Nephrol,2004,36(3):401-405.
[23] Tsutsui S, Kume M, Era S. Prognostic value of microvessel density in invasive ductal carcinoma of the breast.Breast Cancer,2003,10(4):312- 319.
[24] Welter H, Wollenhaupt K, Tiemann U, et al. Regulation of the V EGF2system in the endometrium during steroid2 replacement and early pregnancy of pigs. Exp Clin Endocrinol Diabetes,2003,111(1):33-40.
[25] Evans PW, Wheeler T, Anthony FW, et al. A longitudinal study of maternal serum vascular endothelial growth factor in early pregnancy. Hum Reprod,1998:13:1057-1062.
[26] Kaku T, Kamuta T, Kinukawa N, et al. Angiogenesis in endometrial carcinoma. Cancer,1997,80(4):741-747.
[27] Weidner N, Semple JP, Welch WR, et al. Tumor angiogensis and metastasis-collelation in invasive breast carcinoma. N EngI J Med, 1991,324(1):1-8.
[28] Goddard JC, Sutton CD, Furness PN, et al.A computer image analysis for microvessle density measurement in solid tumours. Angiogensis,2002,5:15-20.
[29] Vamesu S. Angiogenesis and ER/PR status in primary breast cancer patients:an analysis of 158 needle core biopsies. Rom J Morphol Embryol,2007,48(1):25-31.
[30] Jorgensen JM, Sorensen FB, Bendix K, et al.Angiogenesis in non-Hodgkin's lymphomaxlinico-pathological correlations and prognostic significance in specific subtypes.Leuk Lymphoma,2007,48(3):584-595.
[31] Shpitz B, Gochberg S, Neufeld D, et al. Angiogenic switch in earliest stages of human colonic tumorigenesis. Anticancer Res,2003,23(6D):5153-5157.
[32] Messerini L, Nocelli L, Comin CE. Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J Clin Pathol,2004,57(8): 867-871.
[33] Takagi K, Takada T, Amano H. A high peripheral microvessel density count correlates with a poor prognosis in pancreatic cancer. Journal of gastroenterology,2005,40(4):402-408.
[34] Giatromanolaki A, Sivridis E, Koukourakis MI, et al. Prognostic role of angiogenesis in operable carcinoma of the gallbladder . Am J Clin Oncol,2002,25(1):38-41.
[35] Imamura M, Yamamoto H, Nakamura N, et al. Prognostic significance of angiogenesis in gastrointestinal stromal tumor. Mod Pathol,2007,20(5):529-537.
[36] Silvestre JS, Tamarat R, Ebrahimian TG, et al. Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ Res,2003, 93(2):114-123.
[1]Harris J,Werling D,Hope JC,et al.Caveolae and caveolin in immune cells:distribution and functions[J].Trends Immunol,2002,23(3):1582164.
[2]Kiss AL,Turi A,Muller N,et al.Caveolae and caveolin isoforms in rat peritoneal macrophages[J].Micron,2002,33(1):75293.
[3]Razani B,Woodman SE,Lisanti MP.Caveolae:from cell biology to animal physiology[J].Pharmacol Rev,2002,54(3):4312467.
[4]Lavie Y,Fiucci G,Czarny M,et al.Changes in membrane microdomains and caveolae constituents in multidrug resistant cancer cells[J].Lipids,1999,34(1):57-63.
[5]Hatanaka M,Maeda T,Ikemoto T,et al.Expression of caveolin-1 in human T cell leukemia cell lines[J].Biochem Biophys Res Comm,1998,25(3):382-387.
[6]许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6:229-231.
[7]Beer C,Andersen DS,Rojek A,et al.Caveola-Dependent Endocytic Entry of Amphotropic Murine Leukemia Virus[J].Virol,2005,79(16):10776-10787.
[8]Moriyama T,Marquez P,Wakatsuki Yet al.Caveolar Endocytosis Is Critical for BK Virus Infection of Human Renal Proximal Tubular Epithelial Cells[J].Virol 81(16):8552-8562.
[9]Marjom(a|¨)ki V,Pieti(a|¨)inen V,Matilainen H,et al.Internalization of echovirus 1 in caveolae[J].Virol,2002,76(4):1856-65.
[10]Yokomori H,Oda M,Yoshimura K,et al.Elevated expression of caveolin-1 at protein and mRNA level in human cirrhotic liver:relation with nitric oxide [J].Gastro 2003,38(9):854-60.
[11]Ovanessian et al.The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection [J].Immunity,2004,121:617-27.
[12]Sieczkarski SB,Whittaker GR,et al.Influenza virus call enter and infect cells in the absence of clathrin-mediated endocytosis[J].Virol.2002,76:10455-10464.
[13]Yamamoto M,Toya Y,Schwencke C,et all.Caveolin is an activator of insulin receptor signaling[J].Biol Chem,1998,273(41):269622-269681.
[14]Gustavsson J,Parpal S,Karlsson M,et all.Localization of the insulin recep tor in caveolae of adipocyte plasma membranel FASEB[J].1999,13(14):19612-19711.
[15]Smith RM,Harada S,Smith JA,et all.Insulin-induced protein tyrosine phosphorylation cascade and signalling molecules are localized in a caveolin-enriched cell membrane domain[J].Cell Signal,1998,10(5):3552-3621.
[16]Parpal S,KarlssonM,Thorn H,et all.Cholesterol depletion disrupts caveolae and insulin receptor signaling formetabolicontrol via insulin receptor substrate-1,but not for mitogen-activated protein kinase control[J].Biol Chem,2001,276(13):96702-9678
[17]Cohen AW,Razani B,Wang XB,et all.Caveolin-1-deficientmice show insulin resistance and defective insulin receptor protein expression in adipose tissuel[J].PhysiolCell Physiol,2003,285(1):C2222-C2351.
[18]Cohen AW,Park DS,Woodman SE,et all.Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44MAP kinase in cardiac fibroblasts [J].Am J Physiol Cell Physiol,2003,284:C457-74.
[19]庹勤慧,廖端芳.小凹蛋白胞内胆固醇转运复合物的矛盾运动与启示[J].中国医学理论与实践,2005,15(4):504-5.
[20]Frank PG,Lisanti M,1Caveolin-1 and Caveolae in atherosclerosis:differential roles in fatty streak formation and neointimal hyperp lasia[J].CurrOp in Lip idol,2004,15(5):523-9.
[21]冉胤威,杜俊蓉,白波.高胆固醇上调Caveolin-1的表达[J].生物医学工程学杂志,2004,21(2):276-9.
[22]Ushio-FukaiM,Zuo L,Ikeda S,et all.cAbl tyrosine kinase mediates reactive oxygen species and Caveolin-dependent AT1 receptor signaling in vascular smooth muscle:role in vascular hypertrophy[J].Circ Res,2005,1497(8):829-36.
[23]Zuo L,Ushio-FukaiM,Ikeda S,et all.Caveolin-1 is essential for activation of Racl and NAD(P)H oxidase after angiotensin II type 1 receptor stimulation in vascular smooth muscle cells:role in redox signaling and vascular hypertrophy [J].Arterioscler Thromb Vasc Biol,2005,25(9):1824-30.
[24]Chae IH,Park K-W,Kim H-S,et al.Nitric oxide-induced apoptosis is mediated by Bax/Bcl-2 gene expression,transition of cytochrome c,and activation of caspase-3 in rat vascular smooth muscle cells.Clin Chim Acta.2004,341:83-91
[25]Fagan KA,Fouty BW,Tyler RC,et al.The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia[J].Clin Invest.1999,103:291-299.
[26]Razani B,Engelman JA,Wang XB,et al.Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities.J Biol Chem.2001;276:38121-28138.
[27]Park DS,Cohen AW,Frank PG,et al.Caveolin-1 null(-/-) mice show dramatic reduction in the life span. Biochemistry. 2003;42:15124-15131.
[28] Drab M, Verkade P, Elger M, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice.Science. 2001; 293:2449-2452.
[29] Zhao YY, Liu Y, Stan RV, et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci. 2002; 99: 11375-11380.
[30] Kim HP, Wang X, Nakao A, et al. Caveolin-1 expression by means of p38Pmitogen-activated protein kinase mediates the antiproliferative effect of carbon monoxide. Proc Natl Acad Sci. 2005,102:11319-11324.
[31] Mathew R, Huang, Michael H. Gewitz, et al. Pulmonary Artery Hypertension Caveolin-1 and eNOS Interrelationship: A New Perspective. Cardiology in Review 2007,15:143-149.
[32] Bender FC, Reymond MA ,Bron C , et al. Caveolin-1 levels are downregulated in human colon tumors ,and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity [J].Cancer Res,2000,60(20):5870.
[33] Hayashi K, Matsuda S, Machida K, et al. Invasion activating caveolin-1 mutation in human scrirhous breast cancers [J].Cancer Res, 2001,61(6):236122364.
[34] Lee H, Volonte D,Galbiati F,et al. Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site ( Tyr-14) in vivo :identification of a c2Src/ Cav-1/Grb7 signaling cassette[J].Mol Endocrinol,2000, 14(11):1750.
[35] Liscovitch M,Lavie Y. Multidrug resistance:a role for cholesterol efflux pathways [J].Trends Biochem Sci(Review),2000,25(l 1):53
[36] F iucci G, et al. O ncogene 2002;21:2365-2375.
[37] L abrecque L,et al.P roc Am A ssoc Cancer Res 2001;42:835-836.
[38] P ramudji C, et al. Clin Cancer Res 2001;7:4272-4279.
[1]Brkovic a,Sirois MG,et al.Vascular permeability induced by VEGF family members in vivo:role of endogenous PAF and NO synthesis.J Cell Biochem.2007 Feb 15;100(3):727-37.
[2]Wu Y,Zhong Z,Huber J,et al.Anti-vascular endothelial growth factor receptor-1antagonist antibody as a therapeutic agent for cancer.Clin Cancer Res.2006Nov 1;12(21):6573-84.
[3]Gisterek I,Komafel J,et al.VEGF and its receptors as therapeutic target in cancer therapy.Przegl Lek.2006;63(3):155-7.Review.Polish.
[4]Paavonen K,Horelli-Kuitumen N,Chilov D,et al.Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localized to chromosomes 11q13 and 4q34,respectively[J].Circulation,1996,93(6):1079
[5]Iyer S,Scotney PD,Nash AD,et al.Crystal structure of human vascular endothelial growth factor-B:identification of amino acids important for receptor binding[J].J Mol Biol.2006 May 26;359(1):76-85.Epub 2006 Apr 17.
[6]Nash AD,Baca M,Wright C,et al.The biology of vascular endothelial growth factor-B(VEGF-B)[J].Pulm Pharmacol Ther.2006;19(1):61-9.Epub 2005 Apr 25.
[7] P.Salver,A.Lymboussaki and P.Heikkila et al.Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors.Am.J.Pathol. 153(1998).pp. 103-108.
[8] Olofsson B,Pajusola K,Kaipainen A,et al.Vaascular endothelial growth factor B,a novel growth factor for endothelial cells.Pro Natl Acad Sci USA,1996,93(6):2576.
[9] Myake S,Makimuru M,Kanegae Y,et al.Efficient generation of recombinant adenovirus using adenovirus DNA-termunal protein complex and a cosmid bearing the full-length virus genome.Proc Natl Acad Sci USA,1996,93:1320.
[10] Olofsson B,Korpelainen E,Pepper MS,et al.Vascular endothelial growth B(VEGF-B) binds to VEGF receptors-1 and cells.Proc Natl Acad Sci USA,1998,95(20):11709.
[11] Gunningham SP,Currie MJ,Ham C,et al.VEGF-B expression in human primary greast cancer is associated with lymph node metastasis but not angiogenesis[J].J Pathol.2001 Mar;193(3):325-32.
[12] Mylona E,Alexandrou P,Giannopoulou I,et al.The prognostic value of vascular endothelial growth factors(VEGFs)-A and -B and their receptor,VEGFR-1,in invasive breast carcinoma[J].Gynecol Oncol.2007 Mar;104(3):557-63.Epub 2006 Dec 5.
[13] Eleni Mylona,Paraskevi Alexandrou,Loanna Giannopoulou,et al.The prognostic value of vascular endothelial growth factors(VEGFs)-A and-B and their receptor,VEGFR-1,in invasive breast carcinoma[J].Volume 104,Issue 3,March 2007,pages 557-563.
[14] Fitzpatrick TE,Lash GE,Yanaihara A,et al.Inhibition of breast carcinoma and trophoblast cell invasiveness by vascular endothelial growth factor[J].Exp Cell Res.2003 Feb 15;283(2):247-55.
[15] J.S.deJong,P.J.vanDiest,P.vanderValk and J.P.A.Beak. Expression of growth factors,growth receptors and apoptosis related proteins in invasive breast cancer:relation to apoptotic rate.Breast Cancer Res.Treat.66(2001).pp.201-208.
[16] Ai JH,Zheng SG,Zeng YY,et al.The expression and significance of vascular endothelial growth factor and its receptors in hepatocellular carcinoma cell lines with various metastatic potentialities.Zhonghua Gan Zang Bing Zazhi.2008Feb;16(2): 105-8.
[17] Yang AD,Camp ER,Fan F,er al.Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells[J].Cancer Res.2006 Jan 1;66(1):46-51.
[18] Jane S,Wey,M.D,Fan Fan,B.S,Michael J,et al.Vascular endothelial growth facetor receptor-1 promotes migration and invation in pancreatic carcinoma cell lines[J].Volune 104.Issue 2,Pages 427-438.
[19] Wey JS,Fan F,Gray MJ,et al.Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines[J].Cancer.2005 Jul 15;104(2):427-38.
[20] Fan F,Wey JS,MC Carty MF,et al.Expression and function of vascular endothelail growth factor receptor-1 on human colorectal cancer cells[J].Oncogene.2005 Apr 14;24(16):2647-53.
[21] Sun Y,Jin K,Childs JT,et al.Vascular endothelial growth factor-B(VEGF-B) stimulates neurogenesis: evidence from knockout mice and growth factor admiistration[J].Dev Biol.2006 Jan 15;289(2):329-35.Epub 2005 Dec 7.
[22] Aase K,Lymboussaki A,Kaipainen A,et al.Localization of VEGF-B in the mouse embyo suggests a paracrine role of the growth factors in the developing vasculature.Dev Dyn,1999,215(l):12.
[23] Wu Y,Zhong Z,Huber J,Bassi R,et al.Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer[J].Clin Cancer Res.2006 Nov l;12(21):6573-84.
[24] Xuri Li,Ufl Eriksson.Novel VEGF family members:VEGF-B,VEGF-C and VEGF-D[J].Int J biochem & Cell Biology,2001,33(4):421-426.
[25] Felembam A,Sammour A,Tnlandi T,et al.Serum vascular endothelial growth factor levels in early ectopic and in trauterine pregnancies after in vitro fertiliazation treatmentl.Fertility and Sterility,2004,82(2):
[26] Tomanek RJ,Jshii Y,Holifield JS,et al. VEGF family members regulate myocardial tubulogenesis and coronary artery formation in the embryo. Circ Res. 2006 Apr 14;98(7):947-53. Epub 2006 Mar 9.
[27] Riely GJ,Miller VA,et al.Vascular endothelial growth factor trap in non small cell lung cancer[J].Clin Cancer Res.2007 Aug 1;13(15 Pt 2):s4623-7.
[28] Li Y,Zhang F,Naqai N ,et al. VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats.J Clin Invest.2008 Mar 3;118(3):913-923.
[29] Jin K, Mao XO,Greenberg DA,et al. Vascular endothelial growth factor stimulates neurite outgrowth from cerebral cortical neurons via Rho kinase signaling.J Neurobiol.2006 Feb 15;66(3):236-42.
[30]Evans PW,Wheeler T,Anthony FW,et al.A Longitudinal study of metamal serum vascular endothelial growth factor in early pregnancy.Hum Peprod,1998,13:1057.
[31]Welter H,Wollenhaupt K,Tiemann U,et al.Regulation of the V EGF2system in the endometrium during steroid2 replacement and early pregnancy of pigs[J].Exp Clin Endocrinol Diabetes,2003,111(1):33.
[2]Mutsaers SE,Bishop JE,McGrouther G,et al.Mechanisms of tissue repair:from wound healing to fibrosis.Int J Biochem Cell Biol,1997,29(1):5-17.
[3]Grummer R,Hohn HP,Mareel MM,et al.Adhesion and invasion of three human choriocarcinoma cell lines into human endometrium in a three dimensional organ culture system J.Placenta,1994,15:411-429.
[4]Frank PG,Lisanti MP.Caveolin-1 and liver regeneration:role in proliferation and lipogenesis.Cell Cycle,2007,6(2):115-116.
[5]Tsutsui S,Kume M,Era S.Prognostic value of microvessel density in invasive ductal carcinoma of the breast.Breast Cancer,2003,10(4):312-319.
[6]Olofsson B,Pajusola K,Kaipainen A,et al.Vascular endothelial growth factor B,a novel growth factor for endothelial cells.Pro Natl Acad Sci USA,1996,93(6):2576-2581.
[7]Grimmond S,Lagercrantz J,Drinkwater C,et al.Cloning and characterization of a novel human gene related to vascular endothelial growth factor.Genome Res,1996,6:124-131.
[8]Krichevsky AM,Kosik KS.RNAi funcrions in cultured mammalian nurons.Proc Natl Acad Sci USA,2002,99(18):11926-11929.
[9]Wilda M,Fuchs U,Wossmann W,et al.Killing of leukemic cells with a BCR-ABL fusion gene by RNA interference(RNAi).Oncogene,2002,21(37):5716-5724.
[10]Lin SL,Chuong CM,Ying SY.A novel mRNA-cDNA interference phenomenon for silencing bcl-2 expression in human LNCaP cells.Biochem Biophys Res Commun,2001,281(3):639-643.
[1]Higashijima S,Nose A,Eguchi G,et al.Mindin/F spondin family:novel ECM proteins expressed in the zebrafish embryonic axis.Dev Biol,1997,192(2):211-227
[2]Mutsaers SE,Bishop JE,McGrouther G,et al.Mechanisms of tissue repair:from wound healing to fibrosis.Int J Biochem Cell Biol,1997,29(1):5-17.
[3]Grummer R,Hohn HP,Mareel MM,et al.Adhesion and invasion of three human choriocarcinoma cell lines into human endometrium in a three dimensional organ culture system J.Placenta,1994,15:411-429
[4]Yang YJ,Zhang YL,Li X,et al.Contribution of eIF-4E inhibition to the expression and activity of heparanase in human colon adenocarcinoma cell line:LS- 174T.World J Gastroenterol,2003,9(8):1707-1712
[5]Maxhimer JB,Quiros RM,Stewart R,et al.Heparanase-1 expression is associated with the metastatic potential of breast cancer.Surgery,2002,132(2):326-333
[6] Vlodavsky I, Elkin M, Pappo O, et al. Mammalian heparanase as mediator of tumor metastasis and angiogenesis. Isr Med Assoc J,2000,2,suppl:37-45
[7] Zeeberg BR, Feng W, Wang G, et al. GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol,2003,4(4): R28
[8] Borgfeldt C, Casslen B, Liu CL, et al. High tissue content of urokinase plasminogen activator (u-PA) is associated with high stromal expression of u-PA mRNA in poorly differentiated serous ovarian carcinoma. Int J Cancer, 1998,79(6):588-595
[9] O'Toole S, McGuinness E, Sheppard B, et al. Plasminogen activators and inhibitors in ovarian adenocarcinomas. Int J Gynecol Cancer,1999,9(l): 61-66
[10] Borgfeldt C, Hansson SR, Gustavsson B, et al. Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI-1). Int J Cancer,2001,15, 92(4): 497-502
[11] Abendstein B, Daxenbichler G, Windbichler G, et al. Predictive value of uPA,PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients. Anticancer Res, 2000, 20(1B):569-572
[12] Hapke S, Kessler H, Arroyo de Prada N, et al. Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J Biol Chem,2001,13, 276 (28):26340-26348
[13] Delia Porta P, Soeltl R, Krell HW, et al. Combined treatment with serine protease inhibitor aprotinin and matrix metalloproteinase inhibitor Batimastat (BB-94) does not prevent invasion of human esophageal and ovarian carcinoma cells in vivo. Anticancer Res,1999,19(5B):3809-3816
[14] Marshall A, Hodgson J. DNA chips: an array of possibilities. Nat Biotechnol,1998, 16(1):27-31
[15] Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature, 1980, 283 (5743): 139-146
[16] Schena M, Shalon D, Davis RW, et al. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science, 1995, 270(5235):467-470
[17] DeRisi J, Penland L, Brown PO, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet,1996,14(4):457-460
[18]Jingting C,Yangde Z,Yi Z,et al.Heparanase expression correlates with metastatic capability in human choriocarcinoma.Gynecol Oncol,2007,107(1):22-29
[19]Yu R,Zhang Y,Cai JT.Correlation between expression of heparanase and invasion of choriocarcinoma.Zhonghua Fu Chan Ke Za Zhi,2007,42(10):692-695
[20]Diaz LE,Chuan YC,Lewitt M,et al.IGF-Ⅱ regulates metastatic properties of choriocarcinoma cells through the activation of the insulin receptor.Mol Hum Reprod,2007,13(8):567-576
[21]Pongcharoen S,Niumsup P,Sanguansermsri D,et al.The effect of interleukin-17 on the proliferation and invasion of JEG-3 human choriocarcinoma cells.Am J Reprod Immunol,2006,55(4):291-300
[22]Hume DA.The mononuclear phagocyte system.Curr Opin Immunol,2006,18(1):49-53
[23]Patel VP,Lodish HF.A fibronectin matrix is required for differentiation of murine erythroleukemia cells into reticulocytes.J Cell Biol,1987,105(6 Pt 2):3105-3118
[24]Damiano JS,Cress AE,Hazlehurst LA,et al.Cell adhesion mediated drug resistance(CAM-DR):role of integrins and resistance to apoptosis in human myeloma cell lines.Blood,1999,93(5):1658-1667
[25]Sethi T,Rintoul RC,Moore SM,et al.Extracellular matrix proteins protect small cell lung cancer cells against apoptosis:a mechanism for small cell lung cancer growth and drug resistance in vivo.Nat Med,1999,5(6):662-668
[26]Qwarnstr(o|¨)m EE,Ostberg CO,Turk GL,et al.Fibronectin attachment activates the NF-kappa B p50/p65 heterodimer in fibroblasts and smooth muscle cells.J Biol Chem,1994,269(49):30765-30768
[27]Mohri H,Katoh K,Iwamatsu A,et al.The novel recognition site in the C-terminal heparin-binding domain of fibronectin by integrin alpha 4 beta 1receptor on HL-60 cells.Exp Cell Res,1996,222(2):326-332.
[28]Coll JM,Luborsky SW,Mora PT.Metabolically labeled cell membrane proteins in spontaneously and in SV40 virus transformed mouse fibroblasts.Biochemistry,1977,16(14):3169-3177
[29]Liotta LA,Stetler-Stevenson WG.Tumor invasion and metastasis:an imbalance of positive and negative regulation.Cancer Res,1991,51(18 Suppl):5054-5059
[30]Chambers AF,Matrisian LM.Changing views of the role of matrix metalloproteinases in metastasis.J Natl Cancer Inst,1997,89(17):1260- 1270
[31]Parsons SL,Watson SA,Collins HM,et al.Gelatinase(MMP-2 and -9)expression in gastrointestinal malignancy.Br J Cancer,1998,78(11):1495-1502
[32]Nomura H,Fujimoto N,Seiki M,et al.Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2(gelatinase A) in human gastric carcinomas.Int J Cancer,1996,69(1):9-16
[33]Poulsom R,Pignatelli M,Stetler-Stevenson WG,et al.Stromal expression of 72kda type Ⅳ collagenase(MMP-2) and TIMP-2 mRNAs in colorectal neoplasia.Am J Pathol,1992,141(2):389-396
[34]Gohji K,Fujimoto N,Hara I,et al.Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension.Int J Cancer,1998,79(1):96-101
[35]Lampert K,Machein U,Machein MR,et al.Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors.Am J Pathol,1998,153(2):429-37.
[36]陈洪雷,刁路明,陈德基,等.大鼠肺癌侵袭和转移中明胶酶A及其抑制剂的动态表达.中华肿瘤杂志,2002,24(2):118-122.
[37]陈龙邦,李桂圆,王靖华,等.MMP-2和TIMP-2在非小细胞肺癌中的表达及其临床意义.肿瘤防治杂志,2003,10(6):8
[38]Staun-Ram E,Goldman S,Gabarin D,et al.Expression and importance of matrix metalloproteinase 2 and 9(MMP-2 and -9) in human trophoblast invasion.Reprod Biol Endocrinol,2004,2:59
[39]Okamoto T,Niu R,Yamada S,et al.Reduced expression of tissue inhibitor of metalloproteinase(TIMP)-2 in gestational trophoblastic diseases.Mol Hum Reprod,2002,8(4):392-398
[40]Ganesh S,Sier CF,Heerding MM,et al.Prognostic value of the plasminogen activation system in patients with gastric carcinoma.Cancer,1996,77(6):1035-1043
[41]Hong SI,Park IC,Son YS,et al.Expression of urokinase-type plasminogen activator,its receptor,and its inhibitor in gastric adenocarcinoma tissues.J Korean Med Sci,1996,11(1):33-37
[42]He Y,Liu XD,Chen ZY,et al.Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.Clin Cancer Res,2007,13(11):3115-3124
[43]Nekarda H,Schlegel P,Schmitt M,et al.Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.Clin Cancer Res,1998,4(7):1755-1763
[44]周立,芮静安,王少斌,等.尿激酶型纤溶酶原激活剂(uPA)和其受体(uPAR)在肝细胞癌的表达及其临床和病理.中国微创外科杂志,2002,2(6):422-423
[45]van der Burg ME,Henzen-Logmans SC,Berns EM,et al.Expression of urokinase-type plasminogen activator(uPA) and its inhibitor PAI-1 in benign,borderline,malignant primary and metastatic ovarian tumors.Int J Cancer,1996,69(6):475-479
[46]Chambers SK,Ivins CM,Carcangiu ML.Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients.Int J Cancer,1998,79(5):449-454
[47]Gleeson NC,Gonsalves R,Bonnar J.Plasminogen activator inhibitors in endometrial adenocarcinoma.Cancer,1993,72(5):1670-1672
[48]Glenney J R Jr,Zokas L.Nove ltyrosine kinase substrates from Rous Sarcoma Virus-transformed cell are present in the membrane skekton.J Cell Biol,1989,108(6):2401-2408.
[49]Frank PG,Lisanti MP.Caveolin-1 and liver regeneration:role in proliferation and lipogenesis.Cell Cycle,2007,6(2):115-116
[50]Torres VA,Tapia JC,Rodriguez DA,et al.Caveolin-1 controls cell proliferation and cell death by suppressing expression of the inhibitor of apoptosis protein survivin.J Cell Sci,2006,119(Pt9):1812-1823
[51]Iguchi K,Matsunaga S,Nakano T,et al.Inhibition of caveolin-1 expression by incadronate in PC-3 prostate cells.Anticancer Res,2006,26(4B):2977-2981
[52]Kato K,Hida Y,Miyamoto M,et al.Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage.Cancer,2002,94(4):929-933
[53]Kim HA,Kim KH,Lee RA.Expression of caveolin-1 is correlated with Akt-1 in colorectal cancer tissues.Exp Mol Pathol,2006,80(2):165-170
[54]Hayashi K,Matsuda S,Machida K,et al.Invasion activating caveolin-1mutation in human scrirhous breast cancers.Cancer Res,2001,61(6):2361-2364
[55]Brkovic a,Sirois MG.Vascular permeability induced by VEGF family members in vivo:role of endogenous PAF and NO synthesis.J Cell Biochem, 2007,100(3):727-737.
[56]Grimmond S,Lagercrantz J,Drinkwater C,et al.Cloning and characterization of a novel human gene related to vascular endothelial growth factor.Genome Res,1996,6(2):124-131.
[57]Salver P,Lymboussaki A,Heikkila P,et al.Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors.Am J Pathol,1998,153:103-108.
[58]Iyer S,Scotney PD,Nash AD,et al.Crystal structure of human vascular endothelial growth factor-B:identification of amino acids important for receptor binding.J Mol Biol,2006,359(1):76-85.
[59]Olofsson B,Korpelainen E,Pepper MS,et al.Vascular endothelial growth B(VEGF-B) binds to VEGF receptors-1 and cells.Proc Natl Acad Sci USA,1998,95(20):11709-11714.
[60]Gunningham SP,Currie MJ,Ham C,et al.VEGF-B expression in human primary greast cancer is associated with lymph node metastasis but not angiogenesis.J Pathol,2001,193(3):325-332.
[61]Mylona E,Alexandrou P,Giannopoulou I,et al.The prognostic value of vascular endothelial growth factors(VEGFs)-A and -B and their receptor,VEGFR-1,in invasive breast carcinoma.Gynecol Oncol,2007,104(3):557-563.
[62]Mylona E,Alexandrou P,Giannopoulou I,et al.The prognostic value of vascular endothelial growth factors(VEGFs)-A and-B and their receptor,VEGFR-1,in invasive breast carcinoma.Gynecol Oncol,2007,104(3):557-563.
[63]Fitzpatrick TE,Lash GE,Yanaihara A,et al.Inhibition of breast carcinoma and trophoblast cell invasiveness by vascular endothelial growth factor.Exp Cell Res,2003,283(2):247-255.
[64]de Jong JS,van Diest PJ,van der Valk P,et al.Expression of growth factors,growth receptors and apoptosis related proteins in invasive breast cancer:relation to apoptotic rate.Breast Cancer Res Treat,2001,66(3):201-208.
[1]Rajjayabun PH,Garg S,Durkan GC,et al.Caveolin-1 expression is associated with high-grade bladder cancer.Urology,2001,58(5):811-814.
[2]Fra AM,Pasqualetto E,Mancini M,et al.Genomic organization and transcriptional analysis of the human genes coding for caveolin-1 and caveolin-2.Gene,2000,243:75-83.
[3]Hatanaka M,Maeda T,Ikemoto T,et al.Expression of caveolin-1 in human T cell leukemia cell lines.Biochem Biophys Res Comm,1998,253:382-387.
[4]Harris J,Werling D,Hope JC,et al.Caveolae and caveolin in immune cells:distribution and functions.Trends Immuno,2002,23(3):158- 164.
[5]Fujimoto T.Cell biology of caveolae and its implication for clinical medicine.Nagoya J Med Sci,2000,63:9-18.
[6]Bender FC,Reymond MA,Bron C,et al.Caveolin-1 levels are down- regulated in human colon tumors,and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity.Cancer Res,2000,60(20):5870-5878.
[7]Yang G,Truong LD,Timmme TL,et al.Elevated expression of caveolin is associated with prostate and breast cancer.Clin Cancer Res,1998,4(8):1873-1880.
[8]Krichevsky AM,Kosik KS.RNAi funcrions in cultured mammalian nurons.Proc Natl Acad Sci USA,2002,99(18):11926-11929.
[9]Hammond SM,Bernstein E,Beach D,et al.An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells.Nature,2000,404(6775):293-296.
[10]Bernstein E,Caudy AA,Hammond SA,et al.Role for a bidentate ribonuclease in the initiation step of RNA interference.Nature,2001,409(6818):363-366.
[11]Sharp PA.RNA Interference-2001.Cenes Dev,2001,15(5):485-490.
[12]Shi Y.Mammalian RNAi for the masses.Trends Genet,2003,19(1):9- 12.
[13]Brummelkamp TR,Bernards B,Agami R.A system for expression of short interfering RNAs in mammalian cells.Science,2002,296:550-553.
[14]Poste G,Fidler IJ.The pathogenesis of cancer metastasis.Nature,1980,283(5743):139-146.
[15]Glenney JR,Zokas L.Nove Ityrosine kinase substrates from Rous Sarcoma Virus-transformed cell are present in the membrane skekton.J Cell Biol,1989,108(6):2401-2408.
[16]Frank PG,Lisanti MP.Caveolin-1 and liver regeneration:role in proliferation and lipogenesis.Cell Cycle,2007,6(2):115-116.
[17]Torres VA,Tapia JC,Rodriguez DA,et al.Caveolin-1 controls cell proliferation and cell death by suppressing expression of the inhibitor of apoptosis protein survivin.J Cell Sci,2006,119(Pt 9):1812-1823.
[18]Iguchi K,Matsunaga S,Nakano T,et al.Inhibition of caveolin-1 expression by incadronate in PC-3 prostate cells.Anticancer Res,2006,26(4B):2977-2981.
[19]Kato K,Hida Y,Miyamoto M,et al.Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage.Cancer,2002,94(4):929-933.
[20]Kim HA,Kim KH,Lee RA.Expression ofcaveolin-1 is correlated with Akt-1 in colorectal cancer tissues.Exp Mol Pathol,2006,80(2):165-170.
[21]Hayashi K,Matsuda S,Machida K,et al.Invasion activating caveolin-1mutation in human scrirhous breast cancers.Cancer Res,2001,61(6):2361-2364.
[22]Fire A,Xu S,Montgometry MK,et al.Potent and specific genetic interference by double-stranded RNA in Caenarhabditis elegans.Nature,1998,391(6669):806-811.
[23]Philip AB,Sunil SK,David MB.Tissue repair and stem cell renewal in carcinogenesis.Nature,2004,432:324-331.
[24]Yu JY,Deruiter SL,Turner DL.RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells.Proc Natl Acad Sci,2002,99(9):6047-6053.
[25]Couet J,Sargiacomo M,Lisanti MP.Interaction of a receptor tyrosine kinase,EGF-R,with eaveolins Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities.J Biol Chem,2004,272:30428-30438.
[26]Corely-Mastick C,Saltiel AR.Insulin-stimulated tyrosin phosphorylation of caveolin is specific for the differentiated adipocyte phenotype in 3T3-L1 cells.Biol Chem,2005,272:20706-20714.
[27]Wilda M,Fuchs U,Wossmann W,et al.Killing of leukemic cells with a BCR-ABL fusion gene by RNA interference(RNAi).Oncogene,2002,21(37):5716-5724.
[28]Scherr M,Battmer K,Winkler T,et al.Specific inhibition of bcrabl gene expression by small interfering RNA.Blood,2003,101(4):1566-1569.
[29]Wohlbold L,Van Der Kuip H,Miething C,et al.Inhibition of bcr- abl gene expression by small interfering RNA sensitizes for imatinib mesylate(STI571).Blood,2003,102(6):2236-2239.
[30]Brummelkamp TR,Bernards R,Agami R.Stable suppression of tumorigenicity by virus-mediated RNA interference.Cancer Cell,2002,2(3):243-247.
[31]Lin SL,Chuong CM,Ying SY.A novel mRNA-cDNA interference phenomenon for silencing bcl-2 expression in human LNCaP cells.Biochem Biophys Res Commun,2001,281(3):639-643.
[32]Elbashir SM,Harborth J,Lendeckel W,et al.Duplexes of 21- nuckeotide RNAs mediate RNA interference in cultured mammalian cells.Nature,2001,411(6836):494-498.
[33]Kleinman H,MacGarvey M,Hassell J,et al.Basement membrane complexes with biological activity.Biochemistry,1986,25(2):312-318.
[34]Albini A,Iwamoto Y,Kleinman HK,et al.A rapid in vitro assay for quantitating the invasive potential of tumor cells.Cancer Res,1987,47(12):3239-3245.
[35]Rozic JG,Chakraborty C,Lala PK.Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration,incasicenss and angiogenesis.Int J Cancer,2001,93(4):497-506.
[36]Hanna N,Fidler J.Expression of metastatic potential of allogeneic and enogeneic neoplasms in young nude mice.Cancer Res,1981,41(2):438-444.
[1]Anderson WF.Human Gene Therapy.Nature,1998,392(suppl):25-30.
[2]http://www.wiley.co.uk/genmed/clinical
[3]Brkovic a,Sirois MG.Vascular permeability induced by VEGF family members in vivo:role of endogenous PAF and NO synthesis.J Cell Biochem,2007,100(3):727-737.
[4]Wu Y,Zhong Z,Huber J,et al.Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.Clin Cancer Res,2006,12(21):6573-6584.
[5]Gisterek I,Komafel J.VEGF and its receptors as therapeutic target in cancer therapy.Przegl Lek,2006,63(3):155-157.
[6]Weidner N,Semple JP,Welch WR,et al.Tumor angiogenesis and metastasis:correlation in invasive breast carcinoma.N EngI J Med,1999,324:1-8.
[7]Salver P,Lymboussaki A,Heikkila P,et al.Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors.Am J Pathol,1998,153:103-108.
[8]Folkman J.Clinical applications of research on angiogenesis.N EngI J Med,2004,303(26):1757-1763.
[9]Roskoski R Jr.Vascular endothelial growth factor(VEGF) signaling in tumor progression.Crit Rev Oncol Hematol,2007,62(3):179- 213.
[10]Iyer S,Scotney PD,Nash AD,et al.Crystal structure of human vascular endothelial growth factor-B:identification of amino acids important for receptor binding.J Mol Biol,2006,26,359(1):76-85.
[11]Olofsson B,Pajusola K,Kaipainen A,et al.Vascular endothelial growth factor B,a novel growth factor for endothelial cells.Pro Natl Acad Sci USA,1996,93(6):2576-2581.
[12]Miyake S,Makimura M,Kanegae Y,et al.Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci USA,1996,93:1320-1324.
[13] Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA, 1998,95(20): 11709-11714.
[14] Gunningham SP, Currie MJ, Ham C, et al. VEGF-B expression in human primary greast cancer is associated with lymph node metastasis but not angiogenesis.J Pathol,2001,193(3):325-332.
[15] Eleni Mylona, Paraskevi Alexandrou, Loanna Giannopoulou, et al. The prognostic value of vascular endothelial growth factors(VEGFs)-A and -B and their receptor, VEGFR-1,in invasive breast carcinoma. Gynecol Oncol,2007,104(3):557-563.
[16] Fitzpatrick TE, Lash GE, Yanaihara A, et al. Inhibition of breast carcinoma and trophoblast cell invasiveness by vascular endothelial growth factor.Exp Cell Res,2003,283(2):247-255.
[17] deJong JS, vanDiest PJ, vanderValk P, et al. Expression of growth factors,growth receptors and apoptosis related proteins in invasive breast cancer:relation to apoptotic rate. Breast Cancer Res,2001,66:201- 208.
[18] Wey JS, Fan F, Gray MJ, et al. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. Cancer,2005,104(2):427-438.
[19] Ai JH, Zheng SG, Zeng YY, et al. The expression and significance of vascular endothelial growth factor and its receptors in hepatocellular carcinoma cell lines with various metastatic potentialities. Zhonghua Gan Zang Bing Za Zhi,2008,16(2):105-108.
[20] Yang AD, Camp ER, Fan F, et al. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res,2006,66(l):46-51.
[21] Wey JS, Fan F, Gray MJ, et al. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines.Cancer,2005,104(2):427-438.
[22] Canoglu A, Gogus C, Beduk Y, et al. Microvessel density as a prognostic marker in bladder carcinoma: correlation with humor grade, stage and prognosis.Int Urol Nephrol,2004,36(3):401-405.
[23] Tsutsui S, Kume M, Era S. Prognostic value of microvessel density in invasive ductal carcinoma of the breast.Breast Cancer,2003,10(4):312- 319.
[24] Welter H, Wollenhaupt K, Tiemann U, et al. Regulation of the V EGF2system in the endometrium during steroid2 replacement and early pregnancy of pigs. Exp Clin Endocrinol Diabetes,2003,111(1):33-40.
[25] Evans PW, Wheeler T, Anthony FW, et al. A longitudinal study of maternal serum vascular endothelial growth factor in early pregnancy. Hum Reprod,1998:13:1057-1062.
[26] Kaku T, Kamuta T, Kinukawa N, et al. Angiogenesis in endometrial carcinoma. Cancer,1997,80(4):741-747.
[27] Weidner N, Semple JP, Welch WR, et al. Tumor angiogensis and metastasis-collelation in invasive breast carcinoma. N EngI J Med, 1991,324(1):1-8.
[28] Goddard JC, Sutton CD, Furness PN, et al.A computer image analysis for microvessle density measurement in solid tumours. Angiogensis,2002,5:15-20.
[29] Vamesu S. Angiogenesis and ER/PR status in primary breast cancer patients:an analysis of 158 needle core biopsies. Rom J Morphol Embryol,2007,48(1):25-31.
[30] Jorgensen JM, Sorensen FB, Bendix K, et al.Angiogenesis in non-Hodgkin's lymphomaxlinico-pathological correlations and prognostic significance in specific subtypes.Leuk Lymphoma,2007,48(3):584-595.
[31] Shpitz B, Gochberg S, Neufeld D, et al. Angiogenic switch in earliest stages of human colonic tumorigenesis. Anticancer Res,2003,23(6D):5153-5157.
[32] Messerini L, Nocelli L, Comin CE. Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J Clin Pathol,2004,57(8): 867-871.
[33] Takagi K, Takada T, Amano H. A high peripheral microvessel density count correlates with a poor prognosis in pancreatic cancer. Journal of gastroenterology,2005,40(4):402-408.
[34] Giatromanolaki A, Sivridis E, Koukourakis MI, et al. Prognostic role of angiogenesis in operable carcinoma of the gallbladder . Am J Clin Oncol,2002,25(1):38-41.
[35] Imamura M, Yamamoto H, Nakamura N, et al. Prognostic significance of angiogenesis in gastrointestinal stromal tumor. Mod Pathol,2007,20(5):529-537.
[36] Silvestre JS, Tamarat R, Ebrahimian TG, et al. Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ Res,2003, 93(2):114-123.
[1]Harris J,Werling D,Hope JC,et al.Caveolae and caveolin in immune cells:distribution and functions[J].Trends Immunol,2002,23(3):1582164.
[2]Kiss AL,Turi A,Muller N,et al.Caveolae and caveolin isoforms in rat peritoneal macrophages[J].Micron,2002,33(1):75293.
[3]Razani B,Woodman SE,Lisanti MP.Caveolae:from cell biology to animal physiology[J].Pharmacol Rev,2002,54(3):4312467.
[4]Lavie Y,Fiucci G,Czarny M,et al.Changes in membrane microdomains and caveolae constituents in multidrug resistant cancer cells[J].Lipids,1999,34(1):57-63.
[5]Hatanaka M,Maeda T,Ikemoto T,et al.Expression of caveolin-1 in human T cell leukemia cell lines[J].Biochem Biophys Res Comm,1998,25(3):382-387.
[6]许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6:229-231.
[7]Beer C,Andersen DS,Rojek A,et al.Caveola-Dependent Endocytic Entry of Amphotropic Murine Leukemia Virus[J].Virol,2005,79(16):10776-10787.
[8]Moriyama T,Marquez P,Wakatsuki Yet al.Caveolar Endocytosis Is Critical for BK Virus Infection of Human Renal Proximal Tubular Epithelial Cells[J].Virol 81(16):8552-8562.
[9]Marjom(a|¨)ki V,Pieti(a|¨)inen V,Matilainen H,et al.Internalization of echovirus 1 in caveolae[J].Virol,2002,76(4):1856-65.
[10]Yokomori H,Oda M,Yoshimura K,et al.Elevated expression of caveolin-1 at protein and mRNA level in human cirrhotic liver:relation with nitric oxide [J].Gastro 2003,38(9):854-60.
[11]Ovanessian et al.The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B cell epitope vaccine candidate against virus infection [J].Immunity,2004,121:617-27.
[12]Sieczkarski SB,Whittaker GR,et al.Influenza virus call enter and infect cells in the absence of clathrin-mediated endocytosis[J].Virol.2002,76:10455-10464.
[13]Yamamoto M,Toya Y,Schwencke C,et all.Caveolin is an activator of insulin receptor signaling[J].Biol Chem,1998,273(41):269622-269681.
[14]Gustavsson J,Parpal S,Karlsson M,et all.Localization of the insulin recep tor in caveolae of adipocyte plasma membranel FASEB[J].1999,13(14):19612-19711.
[15]Smith RM,Harada S,Smith JA,et all.Insulin-induced protein tyrosine phosphorylation cascade and signalling molecules are localized in a caveolin-enriched cell membrane domain[J].Cell Signal,1998,10(5):3552-3621.
[16]Parpal S,KarlssonM,Thorn H,et all.Cholesterol depletion disrupts caveolae and insulin receptor signaling formetabolicontrol via insulin receptor substrate-1,but not for mitogen-activated protein kinase control[J].Biol Chem,2001,276(13):96702-9678
[17]Cohen AW,Razani B,Wang XB,et all.Caveolin-1-deficientmice show insulin resistance and defective insulin receptor protein expression in adipose tissuel[J].PhysiolCell Physiol,2003,285(1):C2222-C2351.
[18]Cohen AW,Park DS,Woodman SE,et all.Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44MAP kinase in cardiac fibroblasts [J].Am J Physiol Cell Physiol,2003,284:C457-74.
[19]庹勤慧,廖端芳.小凹蛋白胞内胆固醇转运复合物的矛盾运动与启示[J].中国医学理论与实践,2005,15(4):504-5.
[20]Frank PG,Lisanti M,1Caveolin-1 and Caveolae in atherosclerosis:differential roles in fatty streak formation and neointimal hyperp lasia[J].CurrOp in Lip idol,2004,15(5):523-9.
[21]冉胤威,杜俊蓉,白波.高胆固醇上调Caveolin-1的表达[J].生物医学工程学杂志,2004,21(2):276-9.
[22]Ushio-FukaiM,Zuo L,Ikeda S,et all.cAbl tyrosine kinase mediates reactive oxygen species and Caveolin-dependent AT1 receptor signaling in vascular smooth muscle:role in vascular hypertrophy[J].Circ Res,2005,1497(8):829-36.
[23]Zuo L,Ushio-FukaiM,Ikeda S,et all.Caveolin-1 is essential for activation of Racl and NAD(P)H oxidase after angiotensin II type 1 receptor stimulation in vascular smooth muscle cells:role in redox signaling and vascular hypertrophy [J].Arterioscler Thromb Vasc Biol,2005,25(9):1824-30.
[24]Chae IH,Park K-W,Kim H-S,et al.Nitric oxide-induced apoptosis is mediated by Bax/Bcl-2 gene expression,transition of cytochrome c,and activation of caspase-3 in rat vascular smooth muscle cells.Clin Chim Acta.2004,341:83-91
[25]Fagan KA,Fouty BW,Tyler RC,et al.The pulmonary circulation of homozygous or heterozygous eNOS-null mice is hyperresponsive to mild hypoxia[J].Clin Invest.1999,103:291-299.
[26]Razani B,Engelman JA,Wang XB,et al.Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities.J Biol Chem.2001;276:38121-28138.
[27]Park DS,Cohen AW,Frank PG,et al.Caveolin-1 null(-/-) mice show dramatic reduction in the life span. Biochemistry. 2003;42:15124-15131.
[28] Drab M, Verkade P, Elger M, et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice.Science. 2001; 293:2449-2452.
[29] Zhao YY, Liu Y, Stan RV, et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc Natl Acad Sci. 2002; 99: 11375-11380.
[30] Kim HP, Wang X, Nakao A, et al. Caveolin-1 expression by means of p38Pmitogen-activated protein kinase mediates the antiproliferative effect of carbon monoxide. Proc Natl Acad Sci. 2005,102:11319-11324.
[31] Mathew R, Huang, Michael H. Gewitz, et al. Pulmonary Artery Hypertension Caveolin-1 and eNOS Interrelationship: A New Perspective. Cardiology in Review 2007,15:143-149.
[32] Bender FC, Reymond MA ,Bron C , et al. Caveolin-1 levels are downregulated in human colon tumors ,and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity [J].Cancer Res,2000,60(20):5870.
[33] Hayashi K, Matsuda S, Machida K, et al. Invasion activating caveolin-1 mutation in human scrirhous breast cancers [J].Cancer Res, 2001,61(6):236122364.
[34] Lee H, Volonte D,Galbiati F,et al. Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site ( Tyr-14) in vivo :identification of a c2Src/ Cav-1/Grb7 signaling cassette[J].Mol Endocrinol,2000, 14(11):1750.
[35] Liscovitch M,Lavie Y. Multidrug resistance:a role for cholesterol efflux pathways [J].Trends Biochem Sci(Review),2000,25(l 1):53
[36] F iucci G, et al. O ncogene 2002;21:2365-2375.
[37] L abrecque L,et al.P roc Am A ssoc Cancer Res 2001;42:835-836.
[38] P ramudji C, et al. Clin Cancer Res 2001;7:4272-4279.
[1]Brkovic a,Sirois MG,et al.Vascular permeability induced by VEGF family members in vivo:role of endogenous PAF and NO synthesis.J Cell Biochem.2007 Feb 15;100(3):727-37.
[2]Wu Y,Zhong Z,Huber J,et al.Anti-vascular endothelial growth factor receptor-1antagonist antibody as a therapeutic agent for cancer.Clin Cancer Res.2006Nov 1;12(21):6573-84.
[3]Gisterek I,Komafel J,et al.VEGF and its receptors as therapeutic target in cancer therapy.Przegl Lek.2006;63(3):155-7.Review.Polish.
[4]Paavonen K,Horelli-Kuitumen N,Chilov D,et al.Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localized to chromosomes 11q13 and 4q34,respectively[J].Circulation,1996,93(6):1079
[5]Iyer S,Scotney PD,Nash AD,et al.Crystal structure of human vascular endothelial growth factor-B:identification of amino acids important for receptor binding[J].J Mol Biol.2006 May 26;359(1):76-85.Epub 2006 Apr 17.
[6]Nash AD,Baca M,Wright C,et al.The biology of vascular endothelial growth factor-B(VEGF-B)[J].Pulm Pharmacol Ther.2006;19(1):61-9.Epub 2005 Apr 25.
[7] P.Salver,A.Lymboussaki and P.Heikkila et al.Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors.Am.J.Pathol. 153(1998).pp. 103-108.
[8] Olofsson B,Pajusola K,Kaipainen A,et al.Vaascular endothelial growth factor B,a novel growth factor for endothelial cells.Pro Natl Acad Sci USA,1996,93(6):2576.
[9] Myake S,Makimuru M,Kanegae Y,et al.Efficient generation of recombinant adenovirus using adenovirus DNA-termunal protein complex and a cosmid bearing the full-length virus genome.Proc Natl Acad Sci USA,1996,93:1320.
[10] Olofsson B,Korpelainen E,Pepper MS,et al.Vascular endothelial growth B(VEGF-B) binds to VEGF receptors-1 and cells.Proc Natl Acad Sci USA,1998,95(20):11709.
[11] Gunningham SP,Currie MJ,Ham C,et al.VEGF-B expression in human primary greast cancer is associated with lymph node metastasis but not angiogenesis[J].J Pathol.2001 Mar;193(3):325-32.
[12] Mylona E,Alexandrou P,Giannopoulou I,et al.The prognostic value of vascular endothelial growth factors(VEGFs)-A and -B and their receptor,VEGFR-1,in invasive breast carcinoma[J].Gynecol Oncol.2007 Mar;104(3):557-63.Epub 2006 Dec 5.
[13] Eleni Mylona,Paraskevi Alexandrou,Loanna Giannopoulou,et al.The prognostic value of vascular endothelial growth factors(VEGFs)-A and-B and their receptor,VEGFR-1,in invasive breast carcinoma[J].Volume 104,Issue 3,March 2007,pages 557-563.
[14] Fitzpatrick TE,Lash GE,Yanaihara A,et al.Inhibition of breast carcinoma and trophoblast cell invasiveness by vascular endothelial growth factor[J].Exp Cell Res.2003 Feb 15;283(2):247-55.
[15] J.S.deJong,P.J.vanDiest,P.vanderValk and J.P.A.Beak. Expression of growth factors,growth receptors and apoptosis related proteins in invasive breast cancer:relation to apoptotic rate.Breast Cancer Res.Treat.66(2001).pp.201-208.
[16] Ai JH,Zheng SG,Zeng YY,et al.The expression and significance of vascular endothelial growth factor and its receptors in hepatocellular carcinoma cell lines with various metastatic potentialities.Zhonghua Gan Zang Bing Zazhi.2008Feb;16(2): 105-8.
[17] Yang AD,Camp ER,Fan F,er al.Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells[J].Cancer Res.2006 Jan 1;66(1):46-51.
[18] Jane S,Wey,M.D,Fan Fan,B.S,Michael J,et al.Vascular endothelial growth facetor receptor-1 promotes migration and invation in pancreatic carcinoma cell lines[J].Volune 104.Issue 2,Pages 427-438.
[19] Wey JS,Fan F,Gray MJ,et al.Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines[J].Cancer.2005 Jul 15;104(2):427-38.
[20] Fan F,Wey JS,MC Carty MF,et al.Expression and function of vascular endothelail growth factor receptor-1 on human colorectal cancer cells[J].Oncogene.2005 Apr 14;24(16):2647-53.
[21] Sun Y,Jin K,Childs JT,et al.Vascular endothelial growth factor-B(VEGF-B) stimulates neurogenesis: evidence from knockout mice and growth factor admiistration[J].Dev Biol.2006 Jan 15;289(2):329-35.Epub 2005 Dec 7.
[22] Aase K,Lymboussaki A,Kaipainen A,et al.Localization of VEGF-B in the mouse embyo suggests a paracrine role of the growth factors in the developing vasculature.Dev Dyn,1999,215(l):12.
[23] Wu Y,Zhong Z,Huber J,Bassi R,et al.Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer[J].Clin Cancer Res.2006 Nov l;12(21):6573-84.
[24] Xuri Li,Ufl Eriksson.Novel VEGF family members:VEGF-B,VEGF-C and VEGF-D[J].Int J biochem & Cell Biology,2001,33(4):421-426.
[25] Felembam A,Sammour A,Tnlandi T,et al.Serum vascular endothelial growth factor levels in early ectopic and in trauterine pregnancies after in vitro fertiliazation treatmentl.Fertility and Sterility,2004,82(2):
[26] Tomanek RJ,Jshii Y,Holifield JS,et al. VEGF family members regulate myocardial tubulogenesis and coronary artery formation in the embryo. Circ Res. 2006 Apr 14;98(7):947-53. Epub 2006 Mar 9.
[27] Riely GJ,Miller VA,et al.Vascular endothelial growth factor trap in non small cell lung cancer[J].Clin Cancer Res.2007 Aug 1;13(15 Pt 2):s4623-7.
[28] Li Y,Zhang F,Naqai N ,et al. VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats.J Clin Invest.2008 Mar 3;118(3):913-923.
[29] Jin K, Mao XO,Greenberg DA,et al. Vascular endothelial growth factor stimulates neurite outgrowth from cerebral cortical neurons via Rho kinase signaling.J Neurobiol.2006 Feb 15;66(3):236-42.
[30]Evans PW,Wheeler T,Anthony FW,et al.A Longitudinal study of metamal serum vascular endothelial growth factor in early pregnancy.Hum Peprod,1998,13:1057.
[31]Welter H,Wollenhaupt K,Tiemann U,et al.Regulation of the V EGF2system in the endometrium during steroid2 replacement and early pregnancy of pigs[J].Exp Clin Endocrinol Diabetes,2003,111(1):33.